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ABSTRACT 	  
Acute promyelocitic leukemia (APL) is a subtype of acute myeloid leukemia 
characterized in all cases by translocations involving retinoic acid receptors (RAR). 
The most common translocation leads to the fusion of the promyelocytic leukemia 
(PML) and RAR alpha genes. The generated oncofusion protein, PML-RAR (PR), 
corresponds to the initiating event of the transformation. PR expression leads to 
secondary events and causes expansion of immature myeloid progenitors and a 
differentiation block at the promyelocytic stage. The oncogenic potential of PR is at 
least in part due to its ability to function as an aberrant counterpart of RAR. Unlike 
RAR, PR constitutively represses its target genes and is insensitive to physiological 
retinoic acid (RA) stimulation. Pharmacological RA doses, instead, lead to the 
transcriptional induction of its target genes, proteasomal degradation of the fusion 
protein and release of the differentiation block. Indeed RA (in combination with 
chemotherapy and/or arsenic) currently represents the first line treatment for APL 
patients. The proposed model by which PR represses its target genes involves the 
recruitment of several histone modifiers that help to create a chromatin environment 
less permissive for transcription. 
Some of these same chromatin modifiers have been shown to interact with LSD1 in 
many other cellular contexts. LSD1 is a histone demethylase, which catalyzes the 
removal of H3K4me2/me1, whose activity is mainly associated with transcriptional 
repression in several physiological and pathological contexts. Recently, LSD1 
depletion or inactivation has been demonstrated to induce differentiation and 
impairment in the clonogenic activity in models of acute myeloid leukemias (AML). 
The mechanism by which LSD1 leads to increased apoptosis and/or differentiation in 
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leukemia models has yet to be revealed. We found that LSD1 inhibition leads to the 
sensitization of APL cells to physiological concentrations of RA and subsequently to 
differentiation and growth arrest. These effects were even stronger than the ones 
caused by pharmacological doses of RA.  To have mechanistic insights into LSD1's 
role in APL maintenance we took advantage of a potent and specific LSD1 inhibitor 
previously developed by Antonello Mai (University of Roma) and Andrea Mattevi 
(University of Pavia) in collaboration with our lab. First, we assessed whether a pulse 
of LSD1 inhibition was sufficient to prime differentiation. Then we generated data 
sets from several genome wide assays in order to dissect the specific contribution of 
LSD1 in the sensitization of APL cells to physiological concentrations of RA. We 
characterized for the first time the LSD1's genomic distribution in acute myeloid 
leukemia by performing ChIP-Seq experiments. In APL cells LSD1 binds both 
promoters and candidate enhancer regions, and potentially interplays with several TFs 
important for the myeloid lineages functions. Moreover, we found that LSD1 binds 
highly expressed genes and modulates their expression, working mainly as a 
transcriptional co-repressor. Bona fide LSD1 repressed genes are involved in 
differentiation and cell growth control as assessed by ontology pathway analysis. 
LSD1-dependent modulation of gene expression during APL differentiation is in part 
achieved by its ability to control H3K4 methylation. We demonstrated that the 
H3K4me2 regions showing the highest regulation were preferentially distributed in 
TSS distal regions and correspond to the ones presenting the largest overlap with 
LSD1. Of note, these regions were also enriched with TFbs of master regulators of the 
myeloid/monocytic lineage, suggesting their regulatory potential. We also described a 
previously unknown large fraction of common genomic regions bound by LSD1 and 
PR, and a possible role for LSD1 in favouring PR recruitment in the initial phases of 
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disease. Furthermore, PR/LSD1 common binding sites showed peculiar levels of 
H3K4me2 and a subset of them were found to be dynamically regulated, suggesting a 
functional interplay between the two proteins in reshaping the local chromatin 
environment.  
Overall, our findings contribute towards understanding the mechanistic role played by 
LSD1 and of the control of histone methylation during differentiation of 
hematopoietic cells, thereby suggesting new therapeutic strategies for intervention in 
APL and potentially other leukemias. 
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INTRODUCTION 
Epigenetics 
All the cells within a human body are provided with the same DNA sequence, but 
during development they acquire distinct functions and morphologies leading to the 
formation of more than 200 different cell types. The specific cellular phenotype 
clearly does not depend solely upon the genomic sequences that remain unchanged 
during development, but instead mainly depends upon the expression of a specific 
pattern of genes, which must be preserved, strictly controlled and passed down to 
daughter cells in order to maintain the cell identity or to regulate their proper 
differentiation. The mechanism by which these processes (and many others) are 
controlled involves Epigenetics. A number of scientists have provided the community 
with some interpretation of what Epigenetics represents. For example, Conrad 
Waddington coined the term and described Epigenetics as the way by which from the 
genome and its products, the phenotype arises during development (Minucci and 
Pelicci 2006; Goldberg, Allis et al. 2007; Ernst, Kheradpour et al. 2011) he also 
envisaged the differentiation process as a path where the cell faces a combination of 
hills and valleys of energy (representing epigenetic influences) to achieve a more 
specialized phenotype (Figure intro 1). To Artur Riggs and colleagues, the 
hereditability is one of the main features of what should be considered as an 
epigenetic phenomenon.  In fact, they define epigenetics as:  “The study of mitotically 
and/or meiotically heritable changes in gene function that cannot be explained by 
DNA sequence” (Bird 2002). Nowadays a less strict view of epigenetics has evolved 
to also include modifications that result in gene expression alterations that are not 
transmitted throughout the cell cycle and can be relatively short-lived. For example, 
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Bird provides a more general definition of epigenetics that does not necessarily 
include heritability across generations: “the structural adaptation of chromosomal 
regions so as to register, signal or perpetuate altered activity states” (Bird 2007). In 
this view, it becomes essential to understand how the epigenetic platform, shaped by a 
variety of external stimuli, influences cell fate and cellular responses. 
Leading Edge
Essay
Cell 128, February 23, 2007 ©2007 Elsevier Inc. 635
Historically, the word “epigenetics” 
was used to describe events that could 
not be explained by genetic principles. 
Conrad Waddington (1905–1975), who 
is given credit for coining the term, 
defined epigenetics as “the branch 
of biology which studies the causal 
interactions between genes and their 
products, which bring the phenotype 
into being” (Waddington, 1942). Over 
the years, numerous biological phe-
nomena, some considered bizarre and 
inexplicable, have been lumped into the 
category of epigenetics. These include 
seemingly unrelated processes, such 
as paramutation in maize (an interac-
tion between two alleles in which one 
allele causes heritable changes in the 
other allele); position effect variega-
tion in the fruit fly Drosophila (in which 
the local chromatin environment of 
a gene determines its expression); 
and imprinting of specific 
paternal or maternal loci in 
mammals. Although myster-
ies abound, the field is now 
beginning to uncover com-
mon molecular mechanisms 
underlying epigenetic phe-
nomena. We have recently 
witnessed an explosion of 
research efforts, meetings 
and symposia, international 
initiatives, internet resources, 
commercial enterprises, and 
even a recent textbook dedi-
cated to epigenetics, all of 
which lead us to this year’s 
special review issue in Cell. 
What underlies this swell 
of interest in epigenetics? 
Whether it is the enigma of 
epigenetic processes or their 
fundamental importance in 
myriad biological contexts, one thing is 
clear—the field of epigenetics is gain-
ing respect.
Epigenetics, in a broad sense, is a 
bridge between genotype and pheno-
type—a phenomenon that changes the 
final outcome of a locus or chromo-
some without changing the underly-
ing DNA sequence. For example, even 
though the vast majority of cells in a 
multicellular organism share an identi-
cal genotype, organismal development 
generates a diversity of cell types with 
disparate, yet stable, profiles of gene 
expression and distinct cellular func-
tions. Thus, cellular differentiation may 
be considered an epigenetic phenom-
enon, largely governed by changes in 
what Waddington described as the 
“epigenetic landscape” rather than 
alterations i  genetic inheritance (Wad-
dington, 1957; Figure 1). More spe-
cifically, epigenetics may be defined 
as the study of any potentially stable 
and, ideally, heritable change in gene 
expression or cellular phenotype that 
occurs without changes in Watson-
Crick base-pairing of DNA.
Here, we aim to briefly introduce 
some of the core molecular actors 
that play upon the epigenetic stage 
and touch upon concepts of epige-
netic heritability and stability. Despite 
the field’s recent progress, significant 
and fundamental questions remain to 
be answered, many of which center on 
the propagation of epigenetic informa-
tion through cellular division and differ-
entiation. We highlight some of these 
questions as challenges to the emerg-
ing field. We also refer readers to the 
review articles appearing in this special 
issue, as well as a new textbook enti-
tled Epigenetics (Allis et al., 2007; see 
Book Review by Y. Shi, page 
639 of this issue).
Epigenetic Mechanisms  
at Work
Much of today’s epigenetic 
research is converging on 
the study of covalent and 
noncovalent modifications 
of DNA and histone proteins 
and the mechanisms by 
which such modifications 
influence overall chromatin 
structure. Chromatin, the 
complex of DNA and its inti-
mately associated proteins, 
provides an attractive can-
didate for shaping the fea-
tures of a cell’s epigenetic 
landscape (see Review by 
B.E. Bernstein et al., page 
669 of this issue). Diverse 
Epigenetics: A Landscape Takes Shape
Aaron D. Goldberg,1 C. David Allis,1,* and Emily Bernstein1,*
1Laboratory of Chromatin Biology, The Rockefeller University, New York, NY 10021, USA
*Correspondence: alliscd@rockefeller.edu (C.D.A.), bernste@rockefeller.edu (E.B.)
DOI 10.1016/j.cell.2007.02.006
Epigenetics has recently evolved from a collection of diverse phenomena to a defined 
and far-reaching field of study. In this Essay, we examine the epistemology of epigenetics, 
provide a brief overview of underlying molecular mechanisms, and suggest future 
 challenges for the field.
Figure 1. Waddington’s Classical Epigenetic Landscape
In 1957, Conrad Waddington proposed the concept of an epigenetic 
landscape to represent the process of cellular decision-making dur-
ing development. At various points in this dynamic visual metaphor, 
the cell (represented by a ball) can take specific permitted trajecto-
ries, leading to different outcomes or cell fates. Figure reprinted from 
Waddington, 1957.
 
Figure intro 1: Graphical interpretation of epigenetic control of differentiation. The epigenetics 
landscape includes non genetic variations that influence the cell fate during development. In particular, 
the ball represents the cell and the hills and the valleys the epigenetic variables influencing the route of 
the ball and guiding it through to the proper fate.  
 
Chromatin components 
The first level of the epigenetic control of cellular processes falls to chromatin. 
Chromatin is formed by several proteins, which, by dynamic interactions, are 
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responsible for the proper wrapping of the DNA filament. The way in which DNA is 
organized within the nucleus has a strong impact on gene expression and thus on the 
majority of the cellular functions. The basic structural unit of chromatin is the 
nucleosome, which includes approximately 147 base pairs (bp) of DNA wrapped 
around the core particles constituted by histones which are organized in octamers. In 
turn, core histones are formed by a tetramer of H3-H4 histone and a couple of H2A-
H2B histone dimers. The first level of compaction, called “beads on a string,” is 
reached by the assembly of core nucleosomes thanks to fragments of linker DNA. 
Histone H1 binds the DNA linker regions and helps the structure to achieve a higher 
order of compaction, the so called “30nm fiber”. The degree of chromatin wrapping is 
cell type-, differentiation stage- and region- specific. Chromatin within a cell is 
divided in two subtypes according to cytological and functional studies: euchromatin 
and heterochromatin. Euchromatin includes regions rich in genes, more accessible 
and generally more transcribed. Heterochromatin instead, represents highly 
condensed regions and consists mainly of repetitive DNA sequences with a relatively 
low number of genes that are transcriptionally repressed. Functionally, there are two 
types of heterochromatin: the one that remains inactive and condensed during the life 
of the cell, called constitutive, and the one which is inactive and condensed only in 
particular stages of the differentiation process, called facultative. Since the proper 
chromatin organization gives an indispensable contribution to the regulation of the 
cell life cycle, determining the evolution of the cell and its response to external 
stimuli. During evolution eukaryotes have acquired several tools to shape the 
chromatin landscape. Among them there are post-translational modifications of 
histones and DNA (PTMs), and enzymes endowed with chromatin remodelling 
activities. 
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DNA methylation 
DNA methylation represents probably the best characterized epigenetic modification 
and has been described in several organisms (Goldberg, Allis et al. 2007); (Colot and 
Rossignol 1999). DNA methylation is involved in many cellular functions including 
gametogenesis, embryogenesis, X inactivation, imprinting and transcriptional control 
(Bird 2002), (Jones and Takai 2001). This modification shows a peculiar distribution 
in mammals, in fact cytosine residues found within CpGs dinucleotides are 
preferentially methylated. CpG sites are usually clustered in CpGs rich regions and 
defined as CpG islands. CpG islands are mainly distributed around promoters, the 
first exon and the 5’untraslated regions of genes (Esteller 2007) and normally 
protected from methylation. This unmethylated status makes the genes associated 
with CpGs islands prone to be transcriptionally activated, while on the contrary the 
methylation of CpG islands strongly correlates with the silencing of the corresponding 
gene (Esteller 2007). For instance, DNA methylation occurs at alleles which must be 
silenced on the X chromosome (Bird 2002). DNA methyltransferases (DNMTs) are 
the enzymes responsible for the methylation of DNA strands. Mammals have three 
different DNMTs: DNMT1, DNMT3a DNMT3b. DNMT1 regulates the maintenance 
of the methylation status by recognizing hemimethylated DNA (Okano, Bell et al. 
1999); (Bestor 1988). It is involved in heritability of DNA methylation and is 
ubiquitously expressed; DNMT3a and 3b, on the other hand, were initially considered 
as de novo methyltransferases (Okano, Bell et al. 1999), and their expression is 
normally confined to the early stages of development (Meissner, Mikkelsen et al. 
2008) when they are indispensable for the creation of the proper DNA methylation 
status. DNA methylation is indeed one of the major epigenetic players in the 
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differentiation process, in fact the levels of CpG methylation within differentiated 
cells are higher than in stem cells (Mikkelsen et al. 2008; (Mohn, Weber et al. 2008). 
Moreover, the genes mainly subjected to CpG methylation are the ones known to take 
part in the maintenance of pluripotency (Mohn, Weber et al. 2008), (Farthing, Ficz et 
al. 2008). Precisely how the transcriptional silencing depends upon CpGs methylation 
is still not completely understood (Li 2002). It has been shown that DNMTs recruit 
histone modifiers, like histone deacetylases (HDACs) and histone methyltransferases 
(HMTs), together with other co-repressors, to the promoter owing to the methylated 
CpG (Fuks, Burgers et al. 2000); (Burgers, Fuks et al. 2002); (Fuks, Burgers et al. 
2001). Similarly, repressive complexes can also be recruited by methyl-binding 
proteins (Fuks, Burgers et al. 2001); (Magdinier and Wolffe 2001) ; (Fuks, Hurd et al. 
2003). It is possible that the presence of these complexes on the methylated DNA, 
sterically impairs the binding of activator complexes as well as creates a closed 
chromatin conformation thus preventing transcription.  
Quite recently, a new DNA modification has been better characterized, the 5-
hydroxymethylation of cytosine (5hmc) (Branco, Ficz et al. 2012). The enzymes 
responsible for the deposition of this mark belong to the TET family (Tahiliani, Koh 
et al. 2009). The precise role of 5hmc is not fully understood, nevertheless it has been 
hypothesized that this modification represents an intermediate of the demethylation 
process and/or as a proper epigenetic modification recruiting specific transcription 
modulator complexes. (Branco, Ficz et al. 2012). 
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Histone modifications 
Nucleosomes, and in particular single histones show a large number and type of 
modified residues owing to PTMs (Kouzarides 2007). PTMs are predominantly 
localized on the N-terminal tail and include lysine acetylation, methylation, 
sumoylation and ubiquitination; arginine methylation and deamination; 
serine/threonine phosphorylation; ADP ribosylation (Kouzarides 2007). Functionally, 
all of these PTMs contribute to regulating transcription, but the high level of 
complexity makes it difficult to have a global understanding of the related 
mechanism. The complexity is intuitively due to the elevated number of possible 
combination of PTMs, also considering the time of appearance within the cell upon a 
particular stimulus (Kouzarides 2007). Those responsible for the deposition of these 
modifications are several classes of enzymes called “writers”. The “readers” instead, 
are proteins and/or enzymes that can recognize some histone PTMs and induce 
secondary events leading to chromatin alteration and modulation of the transcriptional 
status (Chi, Allis et al. 2010). PTMs can be also dynamically removed by “erasers” 
depending on the functional outcome required by the cell (Chi, Allis et al. 2010). 
“Writers” and “eraser” correspond to several classes of enzymes endowed with 
specialized chromatin modifying activity; the “readers”, instead, are proteins provided 
with a particular domain able to recognize specific modifications (see below) (Figure 
Intro 2). All the proteins cited above can interact directly or be included in the same 
protein complex supporting the idea that the chromatin reshaping derives from an 
interplay of sequential events. (Ruthenburg, Allis et al. 2007); (Yun, Wu et al. 2011);  
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Lysine acetyltransferases, lysine deacetylases and histone acetylation  
Acetylation has been identified more than 40 years ago in eukaryotic cells (Allfrey, 
Faulkner et al. 1964) and nowadays is known to be broadly distributed across species. 
It is respectively deposited and removed on the e-amino group by lysine acetyl-
transferases (KATs) and histone deacetylases (HDACs) (Shahbazian and Grunstein 
2007). HAT and HDAC activities are important also for the control of a 
Nucleus
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regulatory mechanism25. Arginine methylation of his-
tones can promote or antagonize the interaction of 
nuclear factors with other nearby histone marks, thereby 
increasing the complexity of the histone code26,27.
Disease association
The readers, writers and erasers of epigenetic marks can 
contribute to or drive disease via two primary mecha-
nisms. First, aberrant activity due to mutation or altered 
expression of epigenetic factors can alter subsequent 
cellular gene expression patterns that lead to or even 
drive and maintain disease states. Second, because the 
readers, writers and erasers are general factors that work 
in concert with many other cellular proteins, especially 
tissue-specific and environmentally responsive DNA-
binding transcription factors, they can mediate altered 
gene expression patterns driven by upstream signals10. 
Importantly, the latter case offers the opportunity to 
target disease pathways whose primary drivers (for 
example, certain transcription factors or external stimuli) 
may not be druggable.
Cancer. Epigenetic mechanisms have long been known to 
be involved in cancer, beginning with the observation that 
levels of DNA methylation were dramatically altered in 
most cancers. Although cancer is fundamentally a genetic 
disease that is driven by irreversible genomic mutations 
that subsequently activate oncogenes or inactivate tumour 
suppressor genes, there is increasing evidence that many 
epigenetic regulatory proteins are among those dysregu-
lated in cancer, and that histone marks are globally and 
locally altered within cancer epigenomes28.
This knowledge stimulated the development of inhib-
itors of DNA methyltransferases and HDACs that are 
clinically effective in several cancers, attesting to the value 
of epigenetic therapies in oncology28. However, these 
Figure 1 | Covalent modification of histones and DNA are key mechanisms involved in epigenetic regulation of 
gene expression. DNA is packaged into chromatin by wrapping around histone proteins (two copies each of histones 
H2A, H2B, H3 and H4) to form a nucleosome. Nucleosomes are further compacted by additional protein factors to form 
chromatin, with the degree of compactness dependent on the types of post-translational modification present on the 
histones, especially on their terminal residues, which protrude from the nucleosome particle. Acetylated histones tend  
to be less compact and more accessible to RNA polymerase and the transcriptional machinery, thereby enabling 
transcription of nearby genes. Methylated histones can be either repressive or activating, depending on the site and 
degree of methylation. The combination of modifications on each histone and/or nucleosome establishes a code that 
relates to the transcriptional properties of the nearby genes. The primary protein families that mediate histone 
post-translational modifications are illustrated in the inset. Proteins that covalently attach acetyl or methyl groups 
produce (or ‘write’) the code (these include histone acetyltransferases and histone methyltransferases) and are termed 
‘writers’. Proteins that recognize and bind to histone modifications are termed ‘readers’ of the code (these include 
bromodomains, plant homeodomains (PHDs) and members of the royal family of methyl-lysine-binding domains). 
Enzymes that remove histone marks are termed ‘erasers’ (these include histone deacetylases and lysine demethylases). 
REVIEWS
386 | MAY 2012 | VOLUME 11  www.nature.com/reviews/drugdisc
© 2012 Macmillan Publishers Limited. All rights reserved
 
Figure in ro 2. Schematic representation of Writer , Erasers nd Readers. Chromatin related 
proteins responsible for the deposition, removal of the histone PTMs and, in general, the reshaping of 
the histone code (Arrowsmith, Bountra et al. 2012). 
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plethora of non-histone proteins and are involved in different cellular processes, such 
as transcription factor assembly, protein stability and the shuttling between nucleus 
and cytoplasm (Minucci and Pelicci 2006) In particular, two types of KATs have been 
characterized according to their cellular localization: A KATs and B KATs. The first 
group is nuclear, includes the GNAT, MYST and CBP/p300 families and is able to 
acetylate histones and other nuclear proteins. The second group works mainly in the 
cytoplasm and acetylates newly synthesized histones (Rea, Eisenhaber et al. 2000); 
(Nakayama, Rice et al. 2001). Instead, HDACs are subdivided into four classes 
including the following enzymes: Class 1: HDAC 1-3 and HDAC 8; Class II: HDAC 
4-7 and HDAC 9-10; Class III: sirtuin 1-7 and Class IV: HDAC11. Both KATs and 
HDACs principally function within multiprotein complexes (Minucci and Pelicci 
2006), (Rea, Eisenhaber et al. 2000), (Nakayama, Rice et al. 2001) and their catalytic 
activity is influenced by the protein with which they are interacting, by determining 
substrate specificity (Minucci and Pelicci 2006). From the biochemical point of view,  
histone acetylation changes the charge of the substrate, and in particular, in vitro 
studies have shown that acetylation of histones causes an increased distance between 
the two nucleosomes to which they belong. Histone tail-acetylation also contributes to 
chromatin reorganization and is generally associated with transcriptional activation. 
Its action can be exploited indirectly, in fact acetylated histones function as 
recruitment platforms for proteins containing a tandem plant homeodomain (PHD) 
fingers and bromodomains (Marmorstein 2001) (Dhalluin, Carlson et al. 1999). 
Moreover, acetylation cross-talks with other histone PTMs and they reciprocally 
influence their own deposition. An example is given by H3K4methylation, which 
induces H3 acetylation through the recruitment of SAGA and CBP. In turn, H3 
acetylation can promote methylation on the lysine 4 of histone H3 (Murr 2010). 
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Methylation and acetylation can also compete for the binding of the same lysine, in 
particular methylation of H3K9 opposes the transcriptional activation function of the 
H3K9 acetylation (Rea, Eisenhaber et al. 2000), (Nakayama, Rice et al. 2001). 
 
 
 
Lysine methyltransferases, demethylases and histone methylation  
Methylation marks can be deposited both on arginine and lysine residues, and, 
importantly, the number of methyl groups that can be added to histones is variable. 
Arginines can be methylated with one or two groups, and the dimethylated form can 
occur in a symmetrical and asymmetrical conformation (Greer and Shi 2012). 
Lysines, on the other hand, can undergo mono, di- or tri- methylation (Martin and 
Zhang 2005). There are several residues where methylation has been observed, H3K4, 
H3K9 and H3K27 among others. Each methylation status, including the unmodified 
form, has been proposed to have a different correlation with the region specific 
transcriptional outcome (Martin and Zhang 2005). The enzymes responsible for the 
establishment of the histone methylation are the histone methyl transferases (HMTs). 
There are three protein families of HMTs, two acting on lysines residues and one 
working on arginines. Lysines methyltransferases group include both SET [Su(var)3-
9, Enhancer of Zeste, Tritorax] domain containing proteins and the DOT1 family; 
enzymes acting on arginines belong to the protein arginine methyl transferases 
PRMTs family. The methylated residues are instead, actively removed by histone 
demethylases. LSD1, a lysine-specific demethylase acting specifically on the mono 
and di-methylated forms of H3K4, was the first demethylase discovered (Shi, Lan et 
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al. 2004). Several years later Karitinos and colleague characterized a homologue of 
LSD1, LSD2, showing similar biochemical activities on H3K4me1 and H3K4me2 
(Karytinos, Forneris et al. 2009). LSD proteins catalyze demethylation by an amino 
oxidation reaction, using a molecule of flavin adenine dinucleotides (FAD) as a 
cofactor. LSD1 and LSD2 cannot work on trimethylated histones since they need a 
free electron pair to be present upon the lysine residue (Kooistra and Helin 2012). 
Jumanji (JMJ) proteins represent the second family of demethylases. The JMJ family 
consists of 30 members, 18 of which own a JMJ catalytic domain. They can act on 
trimethylated lysines (Mosammaparast and Shi 2010) through  a dioxygenase reaction 
dependent upon Fe(II) and a-ketoglutarate. The ability to recognize specific substrates 
for all the enzymes listed above depends on the protein complexes in which they are 
included. In fact, LSD1 forms a stable complex with several other proteins and is 
involved in different functional outcomes. For instance, LSD1 when bound with the 
corepressor RE1-silencing transcription factor (Co-REST) mediates transcriptional 
repression, but, when recruited by the androgen receptor protein complex, positively 
influence gene activation by demethylating H3K9me2 (Cloos, Christensen et al. 
2008). The methylation and the demethylation are evidently highly regulated and 
histone methylation has an enormous impact on the chromatin landscape assembly 
and, consequently, upon the regulation of gene expression. The methylated forms of 
the histones are recognized by several effector proteins endowed with particular 
domains contributing to both transcriptional activation and repression. Lysine four of 
histone H3, when trimethylated, serves as a mark for the recruitment of the PHD 
doamin-containing BPTF proteins. BPTFs work as subunits of the nucleosome 
remodelling factor (NURF) complex which plays a role in trancriptional activation of 
its target genes (Wysocka, Swigut et al. 2006) HP1 is a chromodomain endowed 
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protein that when bound to methylated H3K9, leads to the formation of 
heterochromatin and is instead, associated with gene silencing (Bannister, Zegerman 
et al. 2001); (Lachner, O'Carroll et al. 2001). Moreover, as previously described in the 
Acetylation section, acetylation and methylation also contribute to shape chromatin  
by influencing each other's deposition and this extensive cross-talk has a strong 
impact on the gene expression. 
 
The first demethylase discovered: LSD1  
Histone methylation was thought to be a stable mark and that its removal could be 
obtained by several mechanisms including DNA replication-dependent dilution or by 
active histone replacement. The first experimental evidence of the existence of direct 
enzymatic demethylation, came with the discovery of LSD1, initially identified as a 
component of the HDAC-BRAF, CoREST complex (You, Tong et al. 2001); (Shi, 
Lan et al. 2004). This demonstration paved the way for the isolation of other 
demethylases: an entire family of demethylases, the JMJ proteins, was discovered 
(Kooistra and Helin 2012). More recently in humans, a homolog of LSD1 was 
characterized enlarging the lysine specific demethylase family. LSD2 exhibits poor 
sequence identity (30%) but similar domain homology with LSD1 (Fang, Barbera et 
al. 2010). The structures of both LSD proteins include a N-terminal SWIRM domain 
and an amino oxidase domain containing two binding sites, one for the substrate and 
another for the FAD molecule. These two pockets together form a globular domain 
responsible for the catalytic activity. LSD proteins remove the monomethyl and 
dimethyl, but not trimethylated form of H3K4 and cause the production of  
formaldehyde and a reduced form of FAD (Fang, Barbera et al. 2010). In addition to 
LSD1, LSD2 contains a zinc-finger domain in its N-terminal region, and vice-versa 
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LSD1 has a TOWER domain that protrudes from its globular portion and is essential 
for its interaction with other proteins. For instance, the TOWER domain mediates the 
binding of LSD1 with Co-REST. Interestingly, this interaction confers nucleosome 
demethylation ability to the purified LSD1 protein and enhances LSD1 stability in 
vivo. On the contrary, LSD1 demethylase ability was found to be impaired when it is 
bound to BHC80 (Shi, Matson et al. 2005). Thus the interaction with co-factors is 
extremely important for the regulation of the LSD1 demethylase activity (Shi, Matson 
et al. 2005). Several other proteins have been characterized as LSD1 interactors and, 
in particular, it is known to be involved in chromatin regulation mediated by a number 
of complexes (CoREST complex, the NURD complex and androgen/oestrogen 
receptor (AR/ER) complex) (see Figure 4).  
 
Figure intro 3. LSD1 works in chromatin modifying complexes to regulate transcription. LSD1 
binds CoREST, NURD and AR/ER complexes and contributes to chromatin and transcriptional 
regulation by demethylating H3K4me2 or H3K9me2. (Adapted from Mosammaparast and Shi Ann 
Rev Biochem 2010) 
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Key histone demethylase complexes and their activities described to date. Green and red circles represent activation- and repression-
associated methyl marks, respectively, and green triangles represent histone acetylation. Solid green lines and dashed red lines represent
enzymatic activities that add or remove specific modifications, respectively. (a) The lysine-specific demethylase 1 (LSD1)-corepressor of
RE1-silencing transcription factor (CoREST) complex. (b) The LSD1-nucleosome remodeling and deacetylase (NuRD) complex.
(c) The LSD1-nuclear hormone receptor (AR/ER) complex. (d ) The mixed-lineage leukemia (MLL) protein-ubiquitously transcribed
tetratricopeptide repeat, X chromosome protein (UTX) complex. (e) The Polycomb repressive complex 2 (PRC2)-retinoblastoma-
binding protein 2 (RBBP2) complex. Abbreviations: AR/ER, androgen receptor/estrogen receptor; Ash2L, absent, small, or homeotic
like 2; BHC80, BRAF and histone deacetylase complex 80; EED, embryonic ectoderm development; EZH2, enhancer of zeste
homolog 2; HDAC1-2, histone deacetylase 1-2; MBD, methyl-CpG-binding domain protein 2; Mi2, myositis autoantigen 2;
MOF, males absent on first; MTA, metastasis associated; PTIP, PAX interacting protein; RbAp, retinoblastoma-associated protein;
RbBP, retinoblastoma-binding protein; SUZ12, suppressor of zeste homolog 12; WDR5, WD repeat domain protein 5.
activity of LSD1 can also be coupled to
chromatin-remodeling Swi/Snf type ATPases
important for transcriptional repression
(Figure 5b). In the NuRD complex, the
metastasis-associated (MTA) proteins function
in place of CoREST and play an analogous
function to allow LSD1 demethylation of
nucleosomal substrates (102). Like CoREST,
the MTA proteins each contain a SANT do-
main, which serve as Myb-like DNA-binding
domains. It is possible that other SANT
domain-containing proteins may serve to
target LSD1 to chromatin.
Although human LSD1 has a clear role in
repression as an H3K4 demethylase, there is
also evidence that it functions as an activator
when present in other complexes, thus playing
opposing roles in different physiological con-
texts. LSD1 has been demonstrated to associate
directly with androgen receptor (AR), and in
this molecular context, LSD1 can demethy-
late H3K9me2/me1 but not H3K4me2/1
(Figure 5c) (103). As a result, transcription
of AR-responsive genes, such as PSA, re-
quires LSD1 for full activation. Interestingly,
this nuclear hormone receptor-mediated gene
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The CoREST complex is composed of HDAC1, BRAF35, BHC80, all of which  are 
thought to play specific roles in the complex. As an example, it has been shown that 
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LSD1 preferentially demethylates deacetylated histones. In keeping with this view, 
HDACs could help to prime chromatin for the LSD1 action (Shi, Matson et al. 2005) 
while CoREST, BRAF35 and BHC80 could instead guide the recruitment of the 
complex to specific genomic loci (Mosammaparast and Shi 2010). Recently, LSD1 
has also been found to cooperate with the NURD complex to control H3K4me2/me1 
levels (Wang, Zhang et al. 2009); (Whyte, Bilodeau et al. 2012). NURD complex also 
contains HDAC activity and shows chromatin remodelling activity specifically thanks 
to the presence of proteins belonging to the SWI/SNF family (Ho and Crabtree 2010). 
In NURD complexes MTA proteins regulate the LSD1 demethylases activity  (Wang, 
Zhang et al. 2009). When interacting both with CoREST and NURD, LSD1 
demethylates the lysine 4 of the histone H3, when instead involved in the AR/ER 
transcriptional regulation its action shifts towards H3K9 (Metzger, Wissmann et al. 
2005); (Garcia-Bassets, Kwon et al. 2007). Until now the ability of LSD1 to likewise 
act upon H3K9 is not supported by biochemical data the human form (Yang, Culhane 
et al. 2007). While H3K4me2 demethylation by LSD1 has been associated with 
transcriptional repression, the activity performed on H3K9me2 seems to be linked to 
gene induction (Cloos, Christensen et al. 2008). LSD1-dependent transcriptional 
control is required for many biological processes with Several reports describing the 
role of LSD1 in differentiation of a great variety of tissues, such as pituitary cells 
(Wang, Scully et al. 2007) and adipogenesis (Musri, Carmona et al. 2010). Moreover, 
Orkin and colleagues used in vitro experiments to uncover the role of LSD1 in the 
multi-lineage hematopoietic differentiation (Saleque, Kim et al. 2007). This role has 
been further explored by conditional KO/KD murine systems confirming a clear 
involvement of LSD1 in several steps of the physiological haematopoietic 
development (Sprussel, Schulte et al. 2012) (Kerenyi, Shao et al 2013) LSD1 
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conditional KD leads to an improper expansion of immature progenitors and an 
impairment in most lineage terminal differentiation.  Interestingly, these defects can 
be reverted by restoring LSD1 expression (Sprussel, Schulte et al. 2012). In 
accordance with this finding, complete deletion of the gene in the hematopoietic 
compartment leads to alteration of HSC self renewal and impairment of terminal 
granulocytic and erythroid maturation. The use of conditional KD systems was 
necessary since LSD1 KO mice are embryonic lethal (Wang, Scully et al. 2007). 
Subsequent studies both in mouse and human KO ESC showed that LSD1 protein 
depletion was associated with proliferation and differentiation defects (Wang, Zhang 
et al. 2009); (Adamo, Sese et al. 2011), (Whyte, Bilodeau et al. 2012). In particular in 
LSD1 KO mESC, an impairment in the proper maintenance of global DNA 
methylation was noted. In this case, LSD1 was shown to regulate the removal of a 
methyl group on K1096 critical for DNMT1 stability and thus for the establishment of 
DNA methylation (Wang, Hevi et al. 2009). LSD1 had been previously shown to act  
upon non-histone substrates in 2007, when Huang and colleagues demonstrated its 
ability to regulate P53 activation by removing K370me2 (Huang, Sengupta et al. 
2007). Later, E2F1 was added to the list of LSD1 substrates, as it was discovered that 
the LSD1 dependent removal of the methyl group from lysine-185 leads to protein 
stabilization and apoptosis (Kontaki and Talianidis 2010). These data highlight the 
wide repertoire of crucial cellular functions in which LSD1 is involved, such as cell 
cycle, differentiation, stem cell regulation, and further support the interest in studying 
how the alterations of its expression/activity could contribute to disease formation or 
maintenance (see paragraph above LSD1 as Drug target).  
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Histone modifications and transcriptional regulation 
As anticipated in the first paragraph describing epigenetics, all chromatin features can 
contribute to regulate the expression pattern and indeed the identity of cells and many 
other processes. In particular, it has been theorized that the plethora of histone 
modifications can influence the expression modulation by a strict interplay. In this 
view the possible combination of PTMs constitutes the “histone code” which must be 
decrypted by chromatin binding proteins to properly regulate the transcriptional 
outcome.  (Jenuwein and Allis 2001); (Strahl and Allis 2000). Histone modifications 
can induce the recruitment of transcription elongation factors as show for H3S10p-
dependent H4K16acetylation, in particular during gene activation (Wysocka, Swigut 
et al. 2006). A great step forward in the decryption of the complex matrix of the 
epigenome has been accomplished thanks to recent advances in high-throughput 
sequencing technology. The possibility to map histone modifications at a 
chromosomal or genomic scale and to generate gene expression information, has lead 
to the identification of chromatin features indicative of both transcribed and repressed 
genes (Figure intro 4). From the regulatory point of view, clear patterns of PTMs have 
been shown to associate with enhancers, promoters and intragenic regions (Ernst, 
Kheradpour et al. 2011). Promoters correspond to cis-regulatory regions spanning the 
transcriptional start site (TSS), which are necessary to guide transcription activation. 
Merging gene expression data and chromatin maps has uncovered a strong association 
between H3K4me3 and H3-H4 acetylation for expressed gene promoters; repressed 
genes, instead show an enrichment of H3K27 and H3K9 trimethylated marks within 
their promoter regions. (Barski, Cuddapah et al. 2007); (Heintzman, Stuart et al. 
2007). Even if H3K4me3 and H3K27me3 seem to be alternatively distributed, in 
early development they coexist in promoters of genes called “bivalent”. These genes 
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are “poised” and later in the differentiation program, could either undergo  activation, 
by the loss of H3K27me3 and the acquistion of H3K4me3 or repression via the  
contrary process (Sharov and Ko 2007).This switch to one or another modification 
status and to a particular transcriptional outcome is strictly regulated by HMTs and 
HDMs, and seems to play a fundamental role in the cell differentiation process. The 
pattern of PTMs associated with enhancers instead, has just started to be understood. 
It includes a combination of high levels of H3K4me1 and low levels of H3K4me3 and 
the binding of P300 associated with these genomic traits (Heintzman, Stuart et al. 
2007). Interestingly, during the early stage of development two additional chromatin 
marks can sub-divide enhancers as being either “poised” when presenting 
H3K27me3, or “active“ when associated with H3K27ac (Rada-Iglesias, Bajpai et al. 
2011); A number of PTMs were also found to associate with other particular genomic 
locations, for example H3k36me3 was found to span the gene body of transcribed 
genes and to be enriched in the 3’ end, suggesting a role in elongation or termination 
(Bannister, Schneider et al. 2005). Naturally, there are also some exceptions to these 
correlations between transcriptional activity and histone PTMs. In fact, when inhibitor 
of growth complex 2 (ING2) binds H3K4me2 and H3K4me3, classically associated 
with gene poising or activation, it stabilizes a histone deacetylase complex and in this 
particular case H3K4me2 and H3K4me3 mediates gene repression (Greer and Shi 
2012). These studies have highlighted some clues about the epigenetic influence on 
gene transcription even if precise and global mechanistic bases still remain to be fully 
elucidated. What is emerging is the very fine regulation needed by the cell in 
controlling chromatin and expression, in fact the epigenetic alteration even of a single 
gene could predispose to diseases, including cancer. 
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Noncoding RNA. Studies in Schizosaccharomyces pombe 
have shown that small RNAs that function as interfering 
RNAs can target and maintain heterochromatin132,133 
(also, see REF. 134 for a recent review). A recent study 
used ChIP–chip to map regions of heterochromatin 
and euchromatin as well as RNAi components and 
small interfering RNAs (siRNAs) across the S. pombe 
genome135. This study confirmed the interdependence 
of RNAi and heterochromatin on a genomic scale. 
Furthermore, recent studies in humans have shown 
that ncRNAs are involved in demarcating active and 
silent chromatin domains136.
Protein binding in relation to chromatin modifications. 
Several techniques discussed in this Review have been 
used to profile the chromatin occupancy of various 
chromatin or DNA-binding proteins (for a recent review 
see REF. 137). The utility of ChIP–chip was originally 
demonstrated by identifying Gal4 and Ste12 binding 
sites in the yeast genome7. The extension of ChIP–chip 
to ChIP–Seq has recently been used to identify binding 
sites for REST (RE1-silencing transcription factor; also 
known as neuron restrictive silencer factor)18, STAT1 
(signal transducer and activator of transcription 1)19 and 
CTCF (CCCTC-binding factor)17, an insulator-binding 
protein, in the human genome.
Another technique — DNA adenine methyltrans-
ferase ID (DamID) — has also been used to identify 
DNA-binding sites on a genomic scale. In this tech-
nique, DNA-binding proteins are first fused to DNA 
adenine methyltransferase (Dam). When the protein 
of interest is expressed in a cell, Dam is targeted to the 
binding sites of this protein where it methylates local 
adenine bases. This local methylation can be detected 
to determine the binding sites of the protein of interest. 
DamID has been used to identify binding sites of HP1 
(heterochromatic protein 1) in the D. melanogaster 
genome138.
An epigenomic picture
Technical progress in genome-wide mapping 
approaches during the past few years has enabled the 
examination of various epigenetic phenomena at a glo-
bal level in various model organisms. Consequently, 
a comprehensive picture of epigenomes is emerging 
(FIG. 5). DNA is methylated throughout the genome 
except at functional regulatory regions, which include 
promoters and enhancers. Large heterochromatin 
domains are associated with widespread H3K9me2 and 
H3K9me3 signals as well as HP1 binding139. Conversely, 
euchromatic domains are associated with localized 
signals of H3K4me as well as H2A.Z and H3.3, occur-
ring mainly at functional regulatory regions such as 
promoters, enhancers and insulators. These functional 
regulatory elements are characterized by DNase I 
hypersensitivity, and active promoters are depleted 
of nucleosomes. The monomethylation of H2BK5, 
H3K9, H3K27 and H4K20 as well as H3K36me3 are 
associated with actively transcribed regions, whereas 
H3K27me3 is widespread across silent genes in 
euchromatic domains.
Nature Reviews | Genetics
Nucleus
H
et
er
oc
hr
om
at
in
Eu
ch
ro
m
at
in
H3K4me3, H3K4me2, 
H3K4me1, H3K9me1,
H2A.Z, H3ac, H4ac
Enhancer
Active geneCpG Island
H3K4me3, H3K4me2,
H3K4me1, H2A.Z, 
H3ac, H4ac
H3K4me1, H4K20me1, 
H3K9me1, H2BK5me1, 
H3K27me1 levels
Inactive gene
DNA-binding
proteinsActiveTranscribed Repressive
Small RNAsDNA methylation HP1
H3K9me3, H3K9me2
H3K36me3
levels
H3K4me3 H3K27me3
Figure 5 | Characteristics of epigenomes. The interaction of DNA methylation, 
histone modification, nucleosome positioning and other factors such as small RNAs 
contribute to an overall epigenome that regulates gene expression and allows  
cells to remember their identity. Chromosomes are divided into accessible regions  
of euchromatin and poorly accessible regions of heterochromatin. Heterochromatic 
regions are marked with histone H3 lysine 9 di- and trimethylation (H3K9me2 and 
H3K9me3), which serve as a platform for HP1 (heterochromatic protein 1) binding. 
Small RNAs have been implicated in the maintenance of heterochromatin. DNA 
methylation is persistent throughout genomes, and is missing only in regions such as 
CpG islands, promoters and possibly enhancers. The H3K27me3 modification is 
present in broad domains that encompass inactive genes. Histone modifications 
including H3K4me3, H3K4me2, H3K4me1 as well as histone acetylation and histone 
variant H2A.Z mark the transcription start site regions of active genes. The 
monomethylations of H3K4, H3K9, H3K27, H4K20 and H2BK5 mark actively 
transcribed regions, peaking near the 5? end of genes. The trimethylation of H3K36 
also marks actively transcribed regions, but peaks near the 3? end of genes.
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Figure intro 4: Chromatin modifications a  associat d with specific functional genomic regions. 
In general chro atin is divided in h terochromatin (mor  compacted and en iched with silenc d genes) 
and in euchromatin, (more accessible and associated with expressed or poised genes). Heterochromatin 
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is mainly associated with H3K9me while the lysine 4, 27 and 36 of histone H3 plus acetylated forms of 
histones are generally enriched in euchromatin. Thanks to genome wide studies it has been possible to 
appreciate such specific distribution of histone/DNA modifications (Schones and Zhao 2008). 
 
Epigenetic alterations in cancer 
 
DNA methylation and histone modifications in cancer 
The epigenetic machinery contributes to regulate most cellular functions and its 
perturbation could lead to improper activation/inhibition of several transcriptional 
pathways, poising or even causing cancer. Cancer cells exhibit profound epigenetic 
abnormalities, including altered methylation. The first suggestion of a role for 
epigenetics in cancer came from an observation by Stephen Baylin. He noticed that 
region specific methylation levels were relatively higher in cancer cells in respect to 
normal cells. He supposed that methylation of a tumor suppressor gene promoter 
would reduce or even stop its transcription. The proof came almost 10 years later via 
a collaboration between Baylin and James Herman studying renal cell carcinomas 
(RCC). In 60% of the cases, RCC is due to inherited silencing mutation of the Von 
Hippen Lindau tumor suppressor gene (VHL). They saw that in the 20% of the cases 
which did not present the mutation, the gene silencing was achieved by 
hypermethylation (Brower 2011). The epigenetic-induced loss of function of tumor 
suppressors caused by hypermethylation, has been found in many other cases such as 
p16, BRCA and Rarβ (Esteller and Herman 2002), (Kulis and Esteller 2010). 
Additionally, many genes involved in DNA repair are subject to this phenomenon, for 
instance MGMT. In response to carcinogen exposure, MGMT catalyzes the removal 
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of O6-methylguanine adducts from DNA. Interestingly, cancers which have MGMT 
promoter-hypermethylation, are susceptible to genetic mutations in specific genes, 
such as p53 or KRAS (Esteller 2007); (Baylin and Jones 2011). Another gene 
undergoing to loss of function by promoter hypermethylation is MLH1. Since it plays 
a role in genomic stability maintenance, its epigenetic depletion can induce several 
cancers, including colorectal and endometrial carcinomas (Krivtsov and Armstrong 
2007). Not only is DNA hypermethylation associated with cancer cell physiology, in 
fact in the mid eighties Feinberg and colleagues, uncovered a global and progressive 
loss of CpG methylation across the genome (Feinberg and Vogelstein 1983). 
Subsequently, it was also shown that the global hypomethylation in gastrointestinal 
cancer correlates with chromosomal instability and DNA damage (Rodriguez, Frigola 
et al. 2006). Another consequence of genome-hypomethylation could be the loss of 
imprinting, as exemplified in the case of insulin-like growth factor 2 gene (IGF2) in 
colorectal cancer (Cui, Horon et al. 1998). Therefore, in tumors, the hypomethylation 
seems to occur in CpG island-negative promoters, introns, repetitive regions and 
transposons (Gama-Sosa, Wang et al. 1983); (Rodriguez, Frigola et al. 2006), while 
DNA hypermethylation is restricted to CpG islands of tumor suppressor gene 
promoters. Moreover, regions located up to 2kb from the nearest gene, called CpG-
shores, were shown to undergo methylation changes in cancer. They show conserved 
methylation profiles between human and mice suggesting a role in the tissue 
specificity (Irizarry, Ladd-Acosta et al. 2009); (Doi, Park et al. 2009). (Baylin and 
Jones 2011); (Esteller 2007). Aberrant histone modification patterns have also been 
found to be associated with several cancer types. In 2005 Fraga and coworkers, 
unveiled a loss of H4K16 acetylation and H4K20me3 in lymphomas and colorectal 
cancer by comparing normal tissues, primary tumors and cancer cell lines, (Fraga, 
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Ballestar et al. 2005). Subsequently, it has been shown that the combination of 5 
histone modifications in prostate cancer biopsies correlates with the patient’s clinical 
outcome (Seligson, Horvath et al. 2005). Moreover, an alteration of H3K9me3 levels 
in core promoters was observed in leukemia when compared to normal samples 
(Muller-Tidow, Klein et al. 2010) and this H3K9me3 pattern strongly contributes, 
along with othner clinical parameters, to determine a more precise prognosis (Muller-
Tidow, Klein et al. 2010) 
 
Genetic alterations of chromatin modifiers 
Thanks to the improvement in sequencing technology the opportunity to extensively 
map cancer genomes has rendered it possible to highlight mutations of several 
chromatin regulators (Dawson and Kouzarides 2012). These mutations can be 
hypothesized to cause a profound alteration of the normal epigenome of the cell at 
several levels. For instance, given the important role of DNMTs proteins in the 
maintenance and deposition of the proper methylation profile, their genetic loci have 
been found to be broadly mutated in many tumors. While DNMT1 mutations have 
been associated with colorectal cancer (Kanai, Ushijima et al. 2003), DNMT3a loss of 
function mutations were found in myelodysplastic syndromes (MDS) and in about 
22% of acute myeloid leukemia (AML) (Ley, Ding et al. 2010); (Yamashita, Yuan et 
al. 2010); (Yan, Xu et al. 2011). In a DNMT3B-depleted cellular context, the Myc-
induced lymphomagenesis was accelerated and SNPs in DNMT3B seem to correlate 
with a higher risk of lung adenocarcinoma (Shen, Wang et al. 2002). On the other 
hand, DNMT3B is also found to be overexpressed in a number of other cancer types: 
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glioblastomas, retinoblastomas, prostate, gastric, colorectal and hepatocellular 
carcinoma (Gros, Fahy et al. 2012). 
A second level of cancer-associated misregulation is represented by the presence of 
aberrant histone modification patterns. The altered balance in the deposition and 
removal of histone marks can be due to improper activity or dosage of the assigned 
modifying enzymes. Truncating mutations associated with loss of heterozygosity of 
P300 have been observed in a number of tumors including glioblastomas and 
colorectal cancer (Phillips and Vousden 2000). Class I HDACs show enhanced 
expression in many solid and hematological malignancies, and in some cases 
overexpression correlates with poor prognosis (Weichert 2009). The expression of 
Class II HDACs, has been reported to be reduced in cancer while their high 
expression levels are associated with better prognosis (Weichert 2009). Among the 
HMTs, mixed lineage leukemia (MLL) is frequently involved in chromosomal 
translocations in acute leukemia (You and Jones 2012). Translocations of MLL can 
cause the formation of fusion proteins that in turn can lead to altered H3K4me3 
deposition. The MLL fusion proteins interact also with other histone modifiers, such 
as DOT1L. This specific interplay induces an aberrant H3K79 methylation pattern 
required for the maintenance of the oncogenic transcriptional program (Bernt, Zhu et 
al. 2011). 
EZH2, an H3K27 methyltransferase, has been observed to be overexpressed in a  
large number of tumor types, which is often associated with tumors in advanced 
stages (Chang and Hung 2012). In particular, EZH2 overexpression in prostate, breast 
lung and bladder tumors leads to an increase of H3K27 methylation. While no 
association between EZH2 and H3K27me3 levels has been found in ovarian and 
pancreatic cancers (You and Jones 2012), EZH2 mutations have been reported in 
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lymphoma and myeloid neoplasms (Chase and Cross 2011). In lymphoma a missense 
mutation within its catalytic domain causes a gain of function, however in myeloid 
malignancies the mutations result in loss of function. 
Similarly, histone demethylase-expression and function has been found to be altered 
in many types of cancer. It was shown that in SUV39 I-II and SUV39H2 (H3K9 
methyltransferases) deficient mice was associated with an increase of B cell 
lymphomas incidence (Peters, O'Carroll et al. 2001). Furthermore, the genomic loci 
corresponding to the JMJD3 and JMJD1 genes are often  often lost in tumors (Cloos, 
Christensen et al. 2008). Importantly, JMJD5 and FBXL10 were identified in mice as 
tumor suppressors of leukemia. (Suzuki, Minehata et al. 2006). On the contrary, 
overexpression of JMJD2A,B,C has been found in prostate cancer (Cloos, Christensen 
et al. 2008). LSD1 also exhibits high expression levels in prostate cancer as well as  
neuroblastoma, bladder cancer, colorectal cancer (Amente, Lania et al. 2013). 
Chromatin remodelers can also contribute to tumor phenotypes as can the many 
irregular transcription factors generated by chromosomal translocations which often 
lead to the alteration of target cell epigenetics via the aberrant recruitment of histone 
modifying proteins. In particular, Acute promyelocytic leukemia (APL) represents the 
first disease in which HDAC involvement in cancer pathology has been demonstrated. 
In APL, the PML-RAR (PR) fusion protein works as a dominant negative counterpart 
of retinoic acid receptor (RAR) and induces a block of myeloid differentiation (see 
paragraphs below). In particular, the PR oncogenic potential is primarily mediated by 
its interaction with the N-COR/HDAC repressor complex (Minucci and Pelicci 2006).   
The PR/HDAC1 interplay likely leads to a general hypoacetylated chromatin 
environment around PR target genes and induces their transcriptional silencing 
(Mikesch, Gronemeyer et al. 2010). The presence of epigenetic enzymes that are 
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overxpressed and seem to function as tumor promoters has made them interesting 
candidates as drug targets. Indeed, the possibility to revert the epigenetic alterations 
thought to be necessary for tumor maintenance represents an intriguing opportunity 
for cancer therapy, which in recent years has been extensively explored. 
 
Histone Modification Machinery
Nucleosomes, which are the basic building blocks of chromatin,
contain DNA wrapped around histones (Luger et al., 1997).
Histones are regulators of chromatin dynamics either by
changing chromatic structure by altering electrostatic charge
or providing protein recognition sites by specific modifications
(Mills, 2010; Suganuma and Workman, 2011). Histone modifica-
tions at specific residues characterize genomic regulatory
regions, such as active promoter regions which are enriched
in trimethylated H3 at lysine 4 (H3K4me3), inactive promoters
which are enriched in trimethylated H3 at lysine 27 (H3K27me3)
or trimethylated H3 at lysine 9 (H3K9me3), and regulatory
enhancers that are enriched in monomethylated H3 at lysine 4
(H3K4me1) and/or acetylatedH3at lysine27 (H3K27ac) (Hawkins
et al., 2011; Hon et al., 2009; Mills, 2010). These histone modif-
ication patterns are regulated by enzymes including histone
acetyltransferases (HATs) and deacetylases (HDACs), which
introduce and remove acetyl groups, respectively. Histonemeth-
yltransferases (HMTs) and demethylases (HDMs), on the other
hand, introduce and remove methyl groups. During tumorigen-
esis, cells undergo global changes in histone modifications and
in the distribution of histone variants such as H2A.Z (Conerly
et al., 2010), which may affect the recruitment of TFs and often
components of the transcriptionmachinery, thereby contributing
to aberrant gene expression (Mills, 2010; Sharma et al., 2010).
The acetylation of lysine residues on histones is generally
associated with active gene transcription. HATs can be grouped
into three categories based on their sequence similarities: Gcn5/
PCAF, p300/CBP, and the MYST families (Yang, 2004). Muta-
tions or translocations of these genes are observed in colon,
uterine, and lung tumors and in leukemias (Esteller, 2007).
Further, these HATs (p300, CBP, and MYST4) are commonly
involved in chromosomal translocations in hematological
cancers rather than in solid tumors (Iyer et al., 2004). For
example, AML1-ETO, the fusion protein generated by the
t(8;21) translocation, which is also the most common fusion
protein in AML, requires its acetylation mediated by p300 for
oncogenic activity (Wang et al., 2011b). HDACs remove acetyl
groups from histone tails, and at least 18 HDAC genes have
been identified in the human genome. HDACs as well as
HATs function as part of large multi-protein complexes (Marks
et al., 2001). HDACs have been implicated in cancer due to
their aberrant binding and consequent silencing of tumor sup-
pressor genes. For example, hypoacetylation of the p21waf1/
cif1 (CDKN1A) promoter results in its silencing and can be
reversed by HDAC inhibitors (Ocker and Schneider-Stock,
2007). Germline mutations of HDACs increase the risk of breast
and lung cancers, and abnormal HDAC overexpression has also
been observed in various cancers (Miremadi et al., 2007). As
a result, HDAC inhibitors have been developed as anti-cancer
drugs (Shankar and Srivastava, 2008). Several independent
reports have identified truncation mutations in HDAC2 in epithe-
lial, colonic, gastric, and endometrial cancers, and these muta-
tions confer resistance to HDAC inhibitors (Smith and Workman,
2009). Screening for thesemutationsmay improve the efficacy of
HDAC inhibitors. Conversely, there is evidence that HDACs may
function as tumor suppressors by maintaining proper chromatin
structure and further stabilizing the genome (Bhaskara et al.,
2010). Potentially, either loss or gain of function mutations of
HDACs could contribute to tumorigenesis.
In addition to chromatin modifying enzymes, chromatin
binding proteins or so-called epigenetic ‘‘readers’’, such as the
bromodomain proteins which read lysine acetylation marks,
can also play an important during tumorigenesis. For example,
the fusion of the bromodomain protein Brd4 with nuclear protein
in testis (NUT) results in the development of aggressive NUT
midline carcinoma (Filippakopoulos et al., 2010). Aberrant regu-
lation of Brd4 has also been reported in other cancers such as
colon and breast, suggesting that the selective inhibitors which
target these kinds of epigenetic readers may give us a novel
clue for cancer therapy (Filippakopoulos et al., 2010; Zuber
et al., 2011).
Methylation of arginine and lysine residues on histones or
nonhistone proteins such as TFs regulate chromatin structure
and therefore gene expression (Greer and Shi, 2012). The best-
known example of alterations in HMTs during tumorigenesis
may be in the mixed lineage leukemia (MLL) protein, which intro-
duces the active H3K4me3 mark and plays important roles in
development. MLL is located on chromosome 11q23, which is
a common region of chromosomal translocation in AML and
ALL (Slany, 2009). Translocations of MLL with multiple different
partners can result in the generation of fusion proteins that are
frequently associated with tumorigenesis and poor prognosis
by generating abnormal patterns of H3K4me3 and/or recruiting
other epigenetic modifiers (Balgobind et al., 2011). These MLL
fusion proteins have close relationships with other epigenetic
modifiers and cause altered epigenetic programs in cancer.
For example, the aberrant H3K79 methylation pattern mediated
by DOT1L is required for the maintenance of the MLL
Figure 2. Genetic Mutations in Epigenetic Modifiers in Cancer
The drawing shows the interaction between epigenetic processes in speci-
fying gene expression patterns. Recent whole exome sequencing studies
show that mutations in the three classes of epigenetic modifiers is frequently
observed in various types of cancers, further highlighting the crosstalk
between genetics and epigenetics. Examples of some but not all of these
mutations that are discussed in this review are shown. The mutations of
epigenetic modifiers probably cause genome-wide epigenetic alterations in
cancer, but these have yet to be demonstrated in a genome-wide scale.
Understanding the relationship of genetic and the epigenetic changes in
cancer will offer novel insights for cancer therapies.
14 Cancer Cell 22, July 10, 2012 ª2012 Elsevier Inc.
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Figure intro 5. Some examples of chromatin modifying proteins found mutated in cancer. Whole 
exome sequencing of several types of tumors have highlighted a close relationship between genetics 
and epigenetics. Many chromatin modifiers have been found mutated in cancer. These mutations 
probably induce severe alterations in the epigenetic landscape of the cells. Epigenetics aberrations, as 
opposed to the genetics aberrations,  can likely be more easily reverted underscoring new opportunities 
for drug design and epigenetic therapies in a wider range of cancers  (You and Jones 2012). 
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Epigenetic inhibitors in cancer therapy 
A number of the previously described genetic alterations within chromatin modifier 
genes are likely “driver mutations” as they are found to be highly represented in 
specific cancer types or in a variety of tumors (Dawson and Kouzarides 2012). The 
resulting epigenetic lesions associated with cancer, as opposed genetic lesions, can be 
potentially reverted and for this reason several drugs targeting chromatin modifiers 
have been developed. Azacitidine (AZA) and decitabine (DAC) are the first approved 
epigenetic drugs. They target DNMT1 and DNMT3 proteins and are currently used as 
standard combined therapies for myelodysplastic syndrome (MDS). What has 
emerged from several phase II and phase III clinical trials in MDS is that, in 
comparison to chemotherapy, the clinical responses occur after multiple therapeutic 
cycles and improve over time with minimal side effects (mainly neutropenia). DAC 
and AZA often in association with standard chemotherapy, have also been tested in 
refractory/relapsed leukemias as well as late stage solid tumors with the most  
promising results seen with previously untreated AML patients (Issa and Kantarjian 
2009). Even if global hypomethylation has been observed upon treatment with 
DNMT inhibitors, there is no correlation with clinical response. Indeed the current 
limit of these two drugs is both the absence of markers to predict patient sensitivity 
and the incomplete understanding of their underlying molecular mechanisms (Issa and 
Kantarjian 2009); (Helin and Dhanak 2013). In the case of HDACi, their use 
anticipated the identification of their molecular target. In fact inhibitors were used to 
isolate the HDAC proteins (Minucci and Pelicci 2006). Nowadays, two HDAC 
inhibitors, suberoylanilide hidroyamic acid (SAHA) and romidepsin (FK228) were 
approved for refracted or relapsed T-cell lymphoma treatment. Other HDAC 
inhibitors have been tested in clinical trials for lymphoma and solid malignancies 
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(Botrugno, Santoro et al. 2009). They showed had shown promising results when 
associated with DNMT inhibitors, but only a limited efficacy in early phases clinical 
trials, both as single therapiesy or in combination with retinoic acid (RA). It is 
possible that the not somewhat unexciting clinical results for HDAC inhibitors are 
duecan be attributed to the lack of the rightan ideal target population (Altucci and 
Minucci 2009), due to the absence of a clear indicator to predictive of clinical 
activityoutcome. , or additionally, to the poor selectivity of the inhibitors, sinceas 
individual HDACs show specific biological functions (Botrugno, Santoro et al. 2009); 
(Helin and Dhanak 2013). Recently, other classes of small molecule inhibitors have 
been developed, including those targeting protein methyltransferases and 
demethylases. Methyltransferases, as described previously, includes PRMTs and 
KMTs. EZH2 belongs to the KMT family and higher expression and somatic 
mutations of EZH2 have been found in lymphomas, and, in solid tumors where they 
correlate with poor prognosis (Helin and Dhanak 2013), (Morin, Johnson et al. 2010), 
(Pasqualucci, Trifonov et al. 2011), (Ryan, Hoff et al. 2010). EZH2 inhibition 
strategies are mainly based on the design of competitive inhibitors. EZH2, in fact, 
shows high affinity for s-adenosyilhomocysteine (SAH) and substrates containing 
lysines. A competitive inhibitor, 3-deazaneplanocin (DZNep), is able to induce 
degradation of the PRC2 protein complex and reactivate PRC2 repressed genes. A 
significant limit of this compound lies in the impossibility to discriminate if the 
associated cellular phenotypes resultant upon treatment  are specifically due to EZH2 
inhibition since all the other functions of the PRC2 complex are impaired (such as 
scaffolding and microRNA binding). Recently, highly potent and specific EZH2 
inhibitors have been derived from high throughput screening and hits optimization 
processes. Some of them have shown also increased bioavailability and in vivo 
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antitumor activity in preclinical studies, and in particular, E7438 has been advanced 
to human clinical trials. (Helin and Dhanak 2013). In the past few years, among the 
lysine demethylases, LSD1 is considered as a really promising target for cancer 
therapy due to advances in understanding its role in tumor progression (Amente, 
Lania et al. 2013). 
 
 
 
LSD1 as a drug target 
As previously described, LSD1 is a FAD-dependent oxidoreductase, which 
demethylates lysine 4 of histone H3. Additionally, LSD1 can act upon lysine 9 of 
histone H3 when associated with the androgen receptor transcriptional regulation 
(Garcia-Bassets, Kwon et al. 2007) (Metzger, Wissmann et al. 2005). From the 
biological point of view, LSD1-depletion causes embryonic lethality in mice (Wang, 
Hevi et al. 2009). LSD1 involvement in cancer has been elucidated recently, with  
expression analyses and immunohistochemistry stainings demonstrating increased 
LSD1 protein/mRNA levels in different types of solid tumors (Amente, Lania et al. 
2013).  In particular, in prostate cancer LSD1 expression serves as a marker for 
cancer recurrence (Kahl, Gullotti et al. 2006), in poorly differentiated neuroblastoma 
tumors it is often found overexpressed (Schulte, Lim et al. 2009) and in non-small cell 
lung cancer its overexpression promotes invasion, progression and proliferation and is 
associated with poor prognosis (Amente, Lania et al. 2013). In these cases LSD1 
inhibition impairs cell growth and tackle its oncogenicity. Consistent with its role as a 
tumor promoter, LSD1 activity was proposed to be involved in the epigenetic 
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reprogramming associated with early phases of EMT transition (McDonald, Wu et al. 
2011). Other studies, on the contrary, have proposed LSD1 as a tumor suppressor. 
Wang and colleagues demonstrated that LSD1 regulates breast cancer cells migration 
and its expression is down regulated in breast carcinomas (Wang, Zhang et al. 2009). 
A number of studies have highlighted the involvement of LSD1 in cellular 
differentiation (Wang, Scully et al. 2007);(Musri, Carmona et al. 2010) and in 
particular in 2007 Saleque and colleagues proposed that LSD1 can repress GFI1 
targets, thus contributing to proper hematopoietic differentiation (Saleque, Kim et al. 
2007). Two recent articles clearly proposed LSD1 as an interesting target for AML 
therapy. By using knock-down and pharmacological approaches, LSD1 targeting, 
alone or in combination with retinoic acid (RA), resulted in the induction of 
differentiation and impairment of clonogenic activity in both murine and human 
primary non-APL AML cells (Schenk, Chen et al. 2012) (Harris, Huang et al. 2012). 
Structurally, LSD1 has a N-terminal SWIRM domain and an enzymatic domain 
including both a FAD- and a substrate- binding pocket (Mosammaparast and Shi 
2010). The most effective compounds developed as LSD1 inhibitors include those 
fitting within the catalytic pocket of the enzyme. They derive from a more general 
monoaminooxidase inhibitor, the tranylcypromine (TCP), already approved for 
depression-treatment (Lee, Wynder et al. 2006), (Binda, Valente et al. 2010), (Harris, 
Huang et al. 2012). We have recently developed a novel LSD1 inhibitor, more 
specific and acting at relatively low concentrations: MC (Binda, Valente et al. 2010. 
We found that LSD1-inhibition enhances sensitivity of a human cell line derived from 
an acute promyelocitic leukemia (APL) patient (NB4 cells) to retinoic acid induced 
growth arrest/differentiation. The mechanism by which LSD1 leads to increased 
apoptosis and/or differentiation in leukemia models still remains to be discovered. 
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Previous studies demonstrated that LSD1 associates with several protein complexes 
among which NURD and CO-REST that are mainly associated with transcriptional 
repression (Amente, Lania et al. 2013). LSD1 inhibition leads to induction of specific 
target genes and is associated with an increase of H3K4me2 at respective promoters, 
but, when associated with androgen- and estrogen- receptor LSD1 seems to act as a 
coactivator via the demethylation of H3K9me2 a modification generally associated 
with stable gene repression (Cloos, Christensen et al. 2008). Other studies have 
demonstrated that LSD1 is able to control transcription by acting as a coactivator. 
Harris and colleagues (Harris, Huang et al. 2012) link the LSD1 inhibition-dependent 
H3K4me2 increase to gene repression, thus pointing out a more intricate mechanism 
of action of LSD1 in the transcription regulation in cancer cells (Harris, Huang et al. 
2012). 
 
Hematopoiesis 
The hematopoietic system shows a strictly regulated hierarchy, where all blood cell 
lineages derive from the hematopoietic stem cells (HSC) (Orkin and Zon 2008).  The 
entire process of hematopoietic differentiation consists in the progressive formation, 
starting from hematopoietic stem cell, of several intermediate progenitor cells (such 
as the common lymphoid progenitor (CLP) and the common myeloid progenitor 
(CMP) that in turn will generate mature hematopoietic populations including B, T and 
natural killer (NK) cells (lymphoid lineage), granulocytes, megakaryocytes, platelets, 
macrophages and erythrocytes (myeloid lineage) (Orkin and Zon 2008); (Rice, 
Hormaeche et al. 2007). Hematopoietic stem cells are able to self renew in order to 
guarantee the appropriate replenishment of the relatively short living mature cells 
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throughout the organism’s entire life (Orkin and Zon 2008). The decision between 
differentiation and self renewal of stem- and- progenitor cells is dependent upon the 
outcome of the highly regulated interplay of several molecular determinants, such as 
external stimuli and transcription factors (TFs) activity. Some TFs are essential for 
maintenance of the stem cell compartment such as SCL/TAL1, LMO2, SET-domain-
containing proteins and the RUNX1 family (Kim and Bresnick 2007); (Orkin 2000) 
while others are considered to be more “lineage specific” including PU.1, C/EBPa 
and GFI-1. GATA1 is necessary for erythroid lineage specification, while PU.1 is 
expressed in HSC, multipotent progenitors, differentiated B cells and is required for 
myeloid differentiation (Rice, Hormaeche et al. 2007). The PU.1 expression pattern 
suggests that the distinction between “stem cell- and lineage-restricted” TFs is not so 
strict. Indeed, the same TF can play a role both in early and in late phases of 
hematopoietic development as well as in multiple lineages (Orkin and Zon 2008); 
(Rice, Hormaeche et al. 2007); (Scott, Simon et al. 1994). TFs often cooperate with 
one another and with chromatin modifiers in order to control epigenetic patterns 
within gene regulatory regions and thus fine-tune the transcription of their target 
genes. For example, during erythroid maturation GATA1 directly recruits protein 
complexes containing HAT activity to the b-globin locus thus facilitating globin 
transcription (Scott, Simon et al. 1994). The majority of TFs and chromatin modifiers 
having a role in hematopoiesis are involved with somatic mutations and chromosomal 
translocations in hematopoietic diseases, including several types of leukemia (Rice, 
Hormaeche et al. 2007). 
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Acute promyelocytic leukemia  
Acute myeloid leukemias (AML) correspond to a group of malignancies characterized 
by impaired hematopoietic differentiation associated with an expansion of abnormal 
progenitors (blasts). Blast infiltration is mainly localized to the bone marrow and 
accompanied often by thrombocytopenia, and anemia. Acute myeloid leukemias very 
frequently are associated with structural chromosomal alterations, such as deletions, 
inversions and translocations. Transformed cells within a patient show the same 
cytogenetic abnormalities supporting the idea that leukemias are indeed clonal 
diseases and that these lesions correspond to early or initiating events in the 
pathogenesis. Translocations can induce TFs misregulation by mislocating the gene 
coding regions in the proximity of regulatory regions normally associated with other 
genes, e.g., c-myc which is placed under the control of immunoglobulin (Igs) gene 
enhancers in Burkitt lymphoma and B-cell leukemia. In myeloid leukemias, it is 
frequently observed that translocations generate chimeric proteins which involve 
transcription factors and chromatin modifiers (Look 1997). Leukemias are classified 
according to two systems: the WHO system that includes morphological, 
immunological, genetic, biologic and clinical information; and the French-American-
British (FAB) classification, based mainly on cytological features of the expanding 
population. Acute promyelocytic leukemia (APL), according to FAB, is included 
within the M3 subtype (Bennett, Young et al. 1997). APL is characterized by 
accumulation of progenitors blocked at the promyelocytic state and by the presence of 
chromosomal translocations involving retinoic acid receptor RAR (Minucci and 
Pelicci 2007). RAR is fused with genes on different chromosomes such as PLZF, 
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NPM and STAT5b (Pandolfi 2001). About 95% of APL patient present the 
translocation t(15:17)(q22;q12). The fusion of these chromosomal branches causes 
the creation of a chimeric gene formed by the promyelocytic leukemia (PML) gene 
and retinoic receptor alpha (RARa) gene, resulting in the PML-RAR (PR) protein (de 
The, Chomienne et al. 1990);  (Kakizuka, Miller et al. 1991). The onset of the disease 
shows constant incidence with age supporting the idea that APL is caused by a single 
rate limiting genetic alteration (Vickers, Jackson et al. 2000). The cell of origin of 
APL has not yet been identified, however in humans it has been proposed to be either 
a T – or myeloid progenitor cell (de The and Chen 2010). PR, in this case, should be 
able to induce lineage switching or induce self renewal properties within progenitor 
cells. In vitro studies have demonstrated that PR confers self renewal abilities to 
murine CMP and GMP progenitors enhancing their colony forming capacity (Welch, 
Yuan et al. 2011). In mice, the expression of PR leads to APL development, albeit 
with variable penetrance and after a “pre-leukemia” stage, suggesting other mutations 
are required for the onset of the disease. For example, a recent work in our lab 
characterized the dual role of HDAC in APL development. HDAC depletion in the 
pre-leukemic phase, works as a tumor suppressor by accelerating the disease onset, 
while HDAC KD post-transformation establishment instead leads to increased 
survival in APL mice (Santoro, Botrugno et al. 2013)   
PML-RAR fusion protein 
PML 
PML	   co-­‐localizes	   with	   several	   proteins	   such	   as	   p53,	   pRb	   and	   CREB-­‐binding	  protein	   (CBP)	   (Zhong,	   Salomoni	   et	   al.	   2000)	   in	   nuclear	   macromolecular	  structures	   called	  nuclear	  bodies	   (NBs).	   	  PML,	   thanks	   to	  RING-­‐,	   zinc	   finger-­‐	   and	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coiled	  coil-­‐	  domains	  shows	  a	  homo-­‐oligomerization	  ability	  which	  is	  responsible	  for	  the	  formation	  NBs	  (Bernardi	  and	  Pandolfi	  2007).	  NBs	  have	  been	  suggested	  to	  play	  a	  role	  in	  the	  cell	  cycle,	  	  the	  control	  of	  apoptosis,	  senescence,	  and	  surveillance	  of	   genomic	   stability	   (Bernardi	   and	  Pandolfi	   2007).	   Studies	  on	   the	  PML	  cellular	  function,	   highlighted	   its	   role	   as	   a	   tumor	   suppressor	   protein	   (Salomoni	   and	  Pandolfi	  2002).	  PML	  deficiency	  in	  thymocytes,	  and	  mouse	  embryonic	  fibroblasts	  induces	  a	  proliferative	  advantage	  (Salomoni	  and	  Pandolfi	  2002).	   In	  various	  cell	  types	   deriving	   from	   PML	   Knock-­‐out	  mice	   it	   has	   been	   observed	   that	   there	   is	   a	  protection	  from	  FAS	  ligand-­‐,	  TNF-­‐,	  and	  INFs-­‐	  dependent	  cell	  death.	  	  Additionally,	  PML-­‐deficient	   mice	   are	   more	   resistant	   to	   anti-­‐FAS	   antibody	   and	   to	   lethal	  exposure	   of	   ionizing	   radiation	   (Wang,	   Ruggero	   et	   al.	   1998).	   PML	   activity	   is	  necessary	   to	   control	   p53	   dependent	   and	   independent	   apoptotic	   pathways	   and	  RAS-­‐induced	  senescence	  (Piazza, Gurrieri et al. 2001).  
RARa 	  
Retinoic acid receptors (RARs) belong to the steroid/thyroid nuclear receptor family. 
There are three isoforms of RARs (RARa, RARb and RARy), RARa alone is  
involved in APL pathogenesis. RARa functions as a nuclear transcription factor, it 
recognizes retinoic acid response elements (RARE) constituted by direct repeats of a 
hexameric sequence spaced by 1 to 5 bp. In vivo studies revealed that the normal 
hematopoietic process is not impaired upon RARs depletion, but that these receptors 
play a role as regulators at different steps of myelopoiesis (Collins 2002). For 
instance, RARa and RARy knock out mice present a block in the terminal 
granulocytic differentiation (Labrecque, Allan et al. 1998). In the absence of retinoic 
acid (RA), RARa represses its target genes while RARb and RARy, both in the 
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absence or presence of RA, function as transcriptional activators (Hauksdottir, 
Farboud et al. 2003). RARa heterodimerizes with retinoid x receptor (RXR) and 
interacts with co-repressor protein complexes such as N-COR and SMRT thus 
imparting HDAC activity. When RA binds RARa, it causes the displacement of co-
repressors and the recruitment of chromatin modifying complexes that act as co-
activators (such as HATs) thereby leading to the transcriptional induction of RAR 
targets (Drumea, Yang et al. 2008); (Hauksdottir, Farboud et al. 2003) 
PML-RAR oncogenic potential 
The	  fusion	  protein	  PR	  contains	  all	  the	  functional	  domains	  of	  both	  of	  the	  parental	  proteins:	  it	  retains	  the	  ability	  to	  bind	  DNA	  and	  to	  interact	  with	  RXR	  of	  RAR	  and	  the	   RING,	   zinc-­‐finger	   and	   coil-­‐coiled	   domain	   of	   PML.	   PR	   leads	   to	   cell	  transformation	  in	  part	  by	  working	  as	  a	  dominant	  negative	  counterpart	  of	  RARa.	  The	  repression	  of	  RAR	  target	  genes	  in	  the	  presence	  of	  PR	  becomes	  constitutive	  since	  PR	  is	  insensitive	  to	  physiological	  concentration	  of	  RA.	  Moreover	  PR	  is	  able	  to	  recruit	  several	  chromatin	  modifier	  proteins	  (such	  as,	  EZH2,	  HDAC1,	  SUV39H1,	  MBD1,	  DNMTs)	   	   that	  help	   to	   repress	   target	   gene	  expression	   (de	  The	  and	  Chen	  2010).	  Pharmacological	  doses	  of	  RA	  are	  needed	  to	  release	  co-­‐repressors	  and	  to	  induce	  recruitment	  of	  co	  activators,	  the	  transcriptional	  reactivation	  of	  the	  target	  genes	   and	   the	   proteosomal-­‐dependent	   degradation	   of	   PR.	   PR	   oligomerization	  through	  the	  PML	  coil-­‐coiled	  domain	  was	  demonstrated	  to	  be	  a	  crucial	  event	  for	  PR	   mediated	   transformation.	   (Minucci,	   Maccarana	   et	   al.	   2000).	   Later,	   it	   was	  discovered	  that	  RAR	  fusion	  proteins	  also	  have	  oligomerization	  domains	  (Kwok,	  Zeisig	  et	  al.	  2006)	  (Licht	  2006).	  The	  oligomerization	  of	  the	  fusion	  protein	  leads	  to	   increased	   affinity	   for	   corepressors,	   partially	   explaining	   the	   resistance	   to	   a	  
	   42	  
physiological	  RA	  stimulus.	  This	  oligomerization	  model	  has	  been	  further	  modified	  by	  the	  discovery	  of	  high	  order	  interactions	  between	  PR	  and	  retinoid	  X	  receptor	  (RXR)	  (Zeisig,	  Kwok	  et	  al.	  2007).	  Two	  studies	  in	  different	  APL	  subtypes	  (one	  in	  PR-­‐expressing	   and	   the	   other	   in	   STAT5-­‐RAR	   translocation-­‐positive	   tumors)	  demonstrated	   that	   x-­‐RAR/RXR	   heterooligomerization	   was	   required	   for	   X-­‐RAR	  fusion’s	  oncogenic	  activity	  (Zhu,	  Nasr	  et	  al.	  2007)	  (Zeisig,	  Kwok	  et	  al.	  2007).	   In	  particular,	  Zhu	  and	  colleague	  generated	  PR	  mutants	  not	  able	  to	  bind	  RXR	  which	  were	  able	  to	  recapitulate	  most	  of	  the	  original	  PR	  oncogenic	  features	  in	  vitro,	  but	  they	   failed	   to	   develop	   APL	   in	   vivo	   (Minucci	   and	   Pelicci	   Cancer	   Cell	   2007).	  Recently,	   our	   lab	   has	   demonstrated	   that	   only	   a	   PML	   coiled-­‐coil	   domain	  dependent	  oligomerization	  of	  RAR	   leads	   to	   in	   vivo	   leukomogenesis	   in	  a	   similar	  extent	   to	   PR	   (Occhionorelli,	   Santoro	   et	   al.	   2011).	   Interestingly,	   Martens	   and	  colleagues	  performed	  ChIP-­‐sequencing	  for	  PR	  and	  RXR	  in	  primary	  APL	  cells	  and	  consequently	   provided	   the	   evidence	   that	   PML-­‐RAR/RXR	   oligomers	   do	   interact	  on	  a	  large	  portion	  of	  genomic	  regions	  (Martens,	  Brinkman	  et	  al.	  2010).	  Another	  report	   characterizing	   the	   genome	   wide	   distribution	   of	   PR,	   found	   that	   PR	   is	  recruited	  to	  non	  canonical	  RAR	  binding	  motif	  thus	  showing	  an	  enlarged	  pattern	  of	  target	  genes	  (relatively	  to	  RAR)	  and	  in	  particular	  has	  been	  suggested	  to	  affect	  PU.1	   dependent	   transcriptional	   control	   (Mikesch,	   Gronemeyer	   et	   al.	   2010).	   PR	  bindings	   seem	   to	   occur	   in	   specific	   genomic	   regions	   characterized	   by	   P300	  binding,	   low	   levels	   of	   acetylated	   histones	   and	   chromatin	   accessibility	   (Saeed,	  Logie	  et	  al.	  2012)	  and	  to	  influence	  their	  local	  epigenetic	  pattern,	  mainly	  acting	  by	  reducing	   acetylation	   (Martens,	   Brinkman	   et	   al.	   2010).	   PR	   oncogenic	   activity	   is	  further	   regulated	  by	  a	  number	  of	  PTMs	  occurring	  within	   its	  different	  moieties.	  While	   the	   PML	   part	   may	   be	   sumoylated,	   the	   RAR	   moiety	   undergoes	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phosphorylation.	   Sumoylation	   leads	   to	   SUMO	   dependent	   recruitment	   of	   death	  domain	  associated	  protein	  (DAXX)	  which	  modulates	  	  apoptosis	  (de	  The	  and	  Chen	  2010).	   Instead,	   Serine	   369	   phosphorylation	   instead,	   is	   important	   for	   the	  recruitment	   of	   TFIIH,	   which	   indirectly	   participates	   in	   the	   RA-­‐dependent	  transcriptional	   activation	   of	   PR	   targets.	   PR	   can	   also	   interfere	   with	   the	  physiological	  PML	  molecular	   functions.	  For	   instance,	   in	  primary	  APL	  blasts,	  PR	  associates	  with	  PML	  endogenous	  proteins	  and	  leads	  to	  the	  disruption	  of	  NBs	  and	  delocalization	  of	  PML	   to	  microspeckles	   (Rego,	  Wang	  et	   al.	   2001;	   Salomoni	   and	  Pandolfi	   2002).	   Indirectly,	   PML	   hemizygosity,	   as	   a	   consequence	   of	   the	  translocation,	  could	  also	  contribute	  to	   the	  APL	  phenotype	  together	  with	  the	  PR	  fusion.	  In	  support	  of	  this	  hypothesis,	  it	  has	  been	  shown	  that	  in	  a	  mouse	  model	  of	  APL,	   the	   progressive	   reduction	   of	   PML	   dosage	   leads	   to	   an	   increase	   in	   the	  incidence	   and	   to	   an	   acceleration	   in	   the	   onset	   of	   PR	   induced	   leukemia.	   (Rego, 
Wang et al. 2001) 
 
APL treatment 
APL is one of the best-characterized malignancies, and represents the best example of  
successful treatment with a targeted therapy. Chemotherapy based on anthracycline 
administration was the first treatment leading to the recovery of some patients. The 
subsequent prognosis of APL patients greatly improved when RA and the pure form 
of arsenic trioxide were introduced as APL treatments in 1985 and 1994, respectively. 
The standard approach for newly diagnosed patients nowadays is represented by RA 
treatment in combination with anthracycline, and the rate of patients experiencing a 
complete remission reaches 95% (Sanz and Lo-Coco 2011). RA treatment, in 
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particular, was introduced before the cloning of the PR fusion protein. The 
translocation generating PR, as described above, is the only genetic lesion always 
present in APL blasts (de	  The	  and	  Chen	  2010).	  Pharmacological concentrations of 
RA induce terminal differentiation of APL cells, PR proteosomal-dependent 
degradation and re-assembly of NBs (de	  The	  and	  Chen	  2010). In some cases, disease 
relapses and RA alone can successfully cure only a few patients. Indeed, while the 
standard cure can reach 70% of effectiveness on relapsed patients, combined 
treatments with both RA and arsenic trioxide, even without chemotherapy, made most 
patients disease-free (de	  The	  and	  Chen	  2010). Molecularly, Arsenic trioxide induces 
the sumoylation of the PML moiety of PR leading to the proteosomal-dependent 
degradation of the oncoprotein (Zhang, Yan et al. 2010) and for this reason, it is only 
effective on PR-positive APL and not in other x-RAR promyelocytic leukemias. A 
number of APL mouse models were developed to understand the mechanistic basis of 
the therapeutic response and to possibly generate new therapeutic approaches. PR 
expression is put under the control of a gene promoter specific for the myeloid 
compartment (cathepsin G or S100A8) (de Thè and Zu, 2010). There is a now well-
established hierarchical organization among the cellular constituents of myeloid 
leukemia. Thanks to transplantation experiments it has become evident that only 
particular cell subpopulations are able to reconstitute the disease in secondary 
recipient mice. These subpopulations harbour leukemia initiating cells  (LIC) 
endowed with self-renewal ability. LICs clearance has been proposed as the final goal 
to accomplish in order to completely eradicate leukemia. RA has been shown to 
induce differentiation and, to a different extent, to impair the self-renewal ability of 
LICs. RA, from the molecular point of view, is able to both activate transcriptional 
responses and to induce PR-degradation while arsenic trioxide induces PR 
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degradation and a partial differentiation (de Thè and Zu, 2010). Recent works 
suggested that the transcriptional activation of PR targets and the PR degradation are 
uncoupled. The first seems to be mainly associated with the differentiation capacity 
while the second seems to instead be responsible for the LIC clearance (Nasr, 
Guillemin et al. 2008) (Ablain, Leiva et al. 2013). Currently, evaluation of the 
combined therapy RA/arsenic tyroxide as a first line treatment is underway. A recent 
report compared classical RA/chemotherapy combination with RA/arsenic trioxide 
treatment in low/to intermediate risk patients and the two combinations seem to show 
comparable results, when comparing two year event free survival rates (Lo-Coco, 
Avvisati et al. 2013). Other alternative therapies are also under investigation, since in 
leukemogenesis, epigenetic enzymes and histone modifications importantly contribute 
to the malignant phenotype (Chen, Odenike et al. 2010), epigenetic targets are being 
used to develop new compounds that, alone or in combination, can be added to the 
standard therapy of APL (Mercurio, Minucci et al. 2010). Preclinical data have  
demonstrated that HDACis induce differentiation of both APL RA-sensitive and -
insensitive cell lines and effectively yielded in vivo remission in RA-resistant APL 
mouse models (Minucci and Pelicci 2006). In the clinics, RA resistance emerges upon 
first line treatment and relapsing patient were then effectively treated with sodium 
phenylbutyrate which was able to restore RA responsiveness (Chen, Odenike et al. 
2010). Although, Phenylbutyrate behaves as a mild HDAC inhibitors, more potent 
compounds, such as hydroxamic acid, cyclic tetrapeptides and benzamides, were 
developed and have been tested in clinical settings (Chen, Odenike et al. 2010). 
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Materials and Methods  
 
Cell culture 
NB4 cells, isolated from an APL patient by Lanotte and colleagues, have 
characteristics similar to APL blasts (Lanotte et al., Blood 1999). NB4 cells were 
grown in RPMI plus 10% of (FCS) fetal calf serum, 2mM glutamine and 1% 
Penicillin/Streptomycin. 
U937(PR9 clone) was previously generated in our laboratory by stable transfection of 
PML/RARα cDNA cloned in the Zinc2+-inducible PINCO plasmid vector as already 
described (Grignani et al., 1996). PR9 cells were grown in RPMI plus 10% of (FCS) 
fetal calf serum, 2mM glutamine and 1% Penicillin/Streptomycin. 
Phoenix-AMPHO are human kidney cells used for the generation of helper-free 
amphotropic retroviruses. Phoenix-AMPHO were grown in DMEM plus FBS 10% 
2mM glutamine and 1% Penicillin/Streptomycin. These cells were used to generate 
LMP retroviral vectors carrying LSD1 interfering sequences.   
Treatments: NB4 cells were plated at 100.000/ml, treated with dimethyl sulfoxide 
(DMSO) 1/1000; with 2µM of LSD1 inhibitor (MC) for 6, 12, 24 or 96h; with RA 
0.01µM (RA LOW) 24 or 96h; with RA 1µM (RA HIGH) for 24 or 96h. RA was 
supplied by Sigma.  
PR9 cells were induced with Zn [100 µM] for 8h and the induction of the PR 
expression was tested by western blot  
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Morphological characterization 
Cytospin preparations obtained from 200.000 cells per sample were stained for 8 
minutes with May-grunwald solution, washed 6 times in deionized water and then 
incubated for 30 min with Giemsa. After three more washes, samples were air dried 
and evaluated. This method of coloration represents the most common way to stain 
blood cells. The two solutions contain a basic dye (methylene blue) and an acid dye 
(eosin). The first carrying a basic net positive charges stain nuclei because of the 
negative charges of phosphate groups of DNA and RNA molecules, basophil granules 
and RNA molecules within the cytoplasm. The eosin carries a net negative charge and 
stains red blood cells and granules of eosinophil granulocytes. We used this kind of 
coloration to assess morphological changes associated with differentiation.   
 
Interfering vectors 
To interfere with LSD1 we tested 4 shRNAmir sequences. We inserted interfering 
sequences onto the LMP vector by XHO-ECORI double digestion. shRNAmir 
transcription in these vectors is RNA Polymerase II (Pol II) mediated and is under the 
control of an LTR promoter and expresses puromycine resistance cassette. LTR is a 
strong promoter able to drive highly effective knockdown of a target gene, even when 
integrated in single copy. The obtained plasmids were used to produce retroviruses 
and to infect NB4 cells 
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Calcium phosphate transfection 
Phoenix-AMPHO Cells are plated at 50% confluence the day before transfection. The 
next day two solutions were prepared, mixed by bubbling and added to the cell plates. 
Solution A: PCAT plasmid (5 µg/10 cm plate), DNA (10 µg/10 cm plate), 61 µl 
CaCl2 and water in a final Volume of 500 µl; Solution B: 500 µl of 2x Hepes-
buffered solution (HBS) 15-20 minutes after mixing they are distributed on the cells. 
Cells are left at 37°C and after 12-16 hours are replenished with fresh medium. 24 
hours and 48h later medium containing the viral supernatant was 
collected/substituted, filtered and stored at 4°C until PEG viral concentration (1 day 
later). 
  
Viral concentration 
Viral concentration was performed by using a 5x PEG solution (System Bioscience). 
1/5 of volume was added to supernatants containing retroviral particles and 
centrifuged at 1500 x g at 4°C for 30min. The pellet was stored in PBS at -80°C . 
 
Spin Infection of NB4 cells 
Cells were put in 24 multiwell plates and plated at a density 500.000 cells in 500 µl of 
medium per well. Virus was diluted in RPMI 10% serum pen/strep in order to add 
500 µl to the cells. Three cycles of infection were performed. Each cycle included a 
45min centrifuge at 1800 rpm and replacement of the old medium with fresh medium 
+ virus particles. At the end of the three cycles, the medium with viral particles was 
removed and substituted with virus-free medium. 24h after infection puromycin 
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selection (2 µg/ml) was performed and resulting in the killing of non-infected cells 
within 48 hours. At this time, cells were then treated with different concentration of 
RA.   
 
Western blot analysis 
Cells were counted and directly lysed in 2X SDS Laemmli buffer (50mM Tris HCl, 
10% glycerol, 2% SDS and water) plus protease inhibitor cocktail. Cell lysate was 
then sonicated by Bioruptor (Diagenode) for 10min. After sonication, samples were 
centrifuged for 15 min at 4°C, 13000 rpm. Lysates were quantified by colorimetric 
methods and protein concentration was assessed as direct function of the 595nm 
absorbance. 80 µg of proteins were mixed with Laemmli (b-mercaptoethanol and 
bromophenol blue) and denaturated for 8 min at 95°C. Cell lysates were loaded onto 
an 7.5% polyacrylamide gel and run in SDS Running Buffer. Transfer to 
nitrocellulose membranes was performed at 100V for 1 hour at 4°C or over night at 
30V in Transfer Buffer containing 20% methanol, After a brief wash in water, 
membranes were blocked in 10% milk/ TBS-Tween for 1 hour at room temperature or 
over night at 4°C and then probed with primary antibodies diluted in TBS-Tween + 
5% milk at 4°C for 2h or over night. After three washes with TBS-Tween (5 minutes 
each), membranes were incubated with the proper secondary antibody in TBS-
Tween+5 % milk for 30 min at room temperature. After 3 more washes, signals were 
revealed using the ECL (Enhanced Chemiluminescence) method. 
Antibodies used for WB:  
 LSD1 Antibody Cell signalling #2139, RAR santa cruz  sc-551  
Tubulin T8328 Sigma 
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ChIP- qPCR/Seq 
Cells were cross-linked in culture medium with 1% formaldehyde in PBS and the 
reaction was stopped after 10 min at RT by adding 0.125 M glycine for 5 min at 4°C. 
The cells were washed twice with PBS and collected by centrifugation. Pellets were 
stored at -80° in SDS buffer (50 mM Tris•HCl pH 8.1, 0.33% SDS, 150mM NaCl, 5 
mM EDTA, and protease inhibitor cocktail) or directly processed. Fixed cells were  
resuspended in IP buffer (100mM tris ph 8.6 0.3% SDS 1.7% TRITON x-100 and 
5mM EDTA). Chromatin was then fragmented to obtain ~300 bp in length by using a 
Branson Sonifier 250. Chromatin pre-clearing was obtained with protein A-sepharose 
beads (Amersham). Then, the supernatant was immunoprecipitated o.n in the presence 
of 30-50 microL of protein G magnetic beads. For histone modification 1 ml 
corresponding to 3x106 cells per each IP and 4ug/ml primary antibody were used; for 
LSD1/PML Chip-Seq 40x106 cells per each IP; 10ug/ml. Before IP 2.5% of input was 
stored at 4% prior to the decrosslinking procedure. Decrosslinking was performed for 
all the IP samples and corresponding inputs, o.n in 0.1%SDS and 0.1% NaCOH3. The 
day after, the enriched DNA was treated with proteinase K at 56°C for 40 min and 
purified with a DNA purification kit (Qiagen). The obtained DNA was then quantified 
by picogreen (see below) and 5-10ng were processed for ChIP-Seq library preparation 
(as described for the Illumina protocol) or used for quantitative real-time PCR (qPCR) 
as follows. 
For the validation of specific regions, ChIP-qPCR were performed as follows. 
Immunoprecipitated DNA was diluted in 9,6µl of H2O per reaction, plus 400 nM 
primers in a final volume of 20µl in SYBR Green. Each ChIP experiment was 
performed at least three times with biological replicates. For ChiP-Seq the immuno 
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precipitated DNA was quantified by picogreen (see below).  
Ab used for ChIP qPCR/Seq: LSD1 17721 abcam; H3K4me2 32356 abcam; PML sc-
5621; Santacruz, IgG sc-2027 
 
 
PicoGreen(pcg) quantification of ChIP DNA. 
This protocol was established with a Glomax fluorometer. This allows for the 
quantification of as few as 25pg/mL of dsDNA. PicoGreen 2x solution was prepared 
by diluting 200x stock in TE (final volume 200µL). A standard DNA curve was 
performed by using genomic DNA as a reference. ChIP DNA generally has a low 
concentration, therefore standard DNA dilutions should range from 25pg/ml up to 
25ng/ml. We prepared a reference sample of 2µg/ml of genomic DNA, which was 
then diluted 40x in TE this stock to get a final 50ng/ml solution. This is further diluted 
½ and then by serial dilution you may obtain 1/10-1/100-1/1000 the last of which 
corresponds to a 25pg/ml concentration. Briefly, we routinely took 2µl from ChIP 
samples, brought the volume to 200µL TE - to have a replica - including total control 
and mock. We then added 100 µL/ml of pcg to each well and incubated 2-5 minutes, 
mixed and further incubated for 2 to 5 minutes at RT, protected from light. After 
reading, we plot a low-range standard curve corrected againist the reagent blank 
fluorescence value. 
 
ChIP-western 
In order to clearly assess if the LSD1 antibody worked properly in our ChIP 
conditions we performed ChIP western keeping similar experimental conditions for 
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our Chromatin IP- qPCR/Seq protocol. IP was performed as for the ChiP-qPCR and 
ChIP-Seq protocol. Briefly, the 60 x 106 crosslinked cells were lysed in SDS buffer 
(2ml) resuspended in IP buffer (3-3.5 ml), sonicated to reach 300bp in length bulk. 
Samples were precleared with protein A-sepharose beads (Amersham). IP was 
performed with the chromatin recovered from 20 x 106 cells and two different 
quantities of Ab were used (5µg and 10 µg) while 5% of the input was kept at 4°C. 
The day after, the same percentage of Input was recovered for the unbound fraction 
/5%).  IP samples were washed and beads with enriched chromatin fractions, IPs, 
unbound fractions and inputs were decrossilinked directly in Laemmli buffer (2X) and 
loaded onto an SDS page 7.5%. The membrane was then processed as described 
above (see Western blot)  
Ab used: LSD1 17721 abcam; IgG sc-2027 Santacruz 
 
RNA extraction and qPCR 
Total RNA was extracted from NB4 cells with Trizol reagent (Invitrogen) and then 
purified using the RNeasy kit (Quiagen). To remove residual genomic DNA, on 
column DNAseI digestion was performed (Quiagen Kit). Reverse transcription was 
performed with Superscript II Kit (Invitrogen), according to the manufacturer’s 
protocol. qPCR were performed in triplicates in 20 µL of final reaction volume 
containing SYBR green buffer (Applied Biosystems), 20 ng of cDNA retrotrancribed 
from the RNA, and 0.4µM of each primer mix. All the qPCR amplifications were 
performed in the AB-7000 sequence detection system (Applied Biosystem) at 50°C 
for 2 minutes 95°C for 10 min followed by 40 cycles at 95°C. 
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RNA-seq protocol 
mRNA-seq was performed according to the True-seq Low sample protocol selecting 
only polyadenylated transcripts. In brief, before starting mRNA isolation and library 
preparations the integrity of the total RNA was evaluated by running samples on a 
Bioanalyzer. Then, starting from 1µg of RNA isolated as described above (see RNA 
extraction), poly-T oligos attached to magnetic beads were used to purify mRNAs. 
Two rounds of isolation were performed by denaturing and letting the RNA bind to 
poly-T oligos conjugated to the beads. After the second round, RNA was fragmented 
and primed with random hexamers. Immediately after, we proceeded with the first 
strand synthesis by using Superscript II reverse transcriptase and random primers. The 
subsequent second strand synthesis led to the elimination of RNA molecules and the 
formation of cDNA. The subsequent isolation of the cDNA was achieved by using 
AMPure XP beads (depending on the concentration used, these beads can efficiently 
recover PCR products of different sizes). The product recovered contained 
overhanging strands of various length due to the fragmentation procedure. Thanks to 
the 3’-5’ exonuclease activity and the polymerase activity the cDNA ends were 
efficiently converted into blunt ends. The following steps follow the classical protocol 
for Illumina library preparations: adenylation of the 3’ ends plus adapter ligation was 
then followed by a short amplification step to enrich the DNA fragments.  
 
ChIP- Seq analysis 
Raw data corresponding to reads coming from Illumina Genome Analyizer II were 
analyzed according to the Fish the ChIPs pipeline (Barozzi et al., 2011). The 
automated procedure includes alignment to Human NCBI36/hg18. To exclude PCR 
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reads coming from library production, only sequences showing unique alignment 
were used for peak calling, allowing for a maximum of two mismatches. MACS 
(Zhang et 2008) was used for peaks detection. For LSD1 ChiP-Seq in NB4 cells 
according to our validation analysis we set a stringent threshold; pvalue ≤ 0.017, 
while for the all other ChIP-seq p-value ≤ 0.05.  The reads from each sample were 
normalized to the input of the corresponding cell line. For the detection of IMRs or 
for the changes in the LSD1 recruitment the signals were normalized ChIP vs ChIP 
and only regions that were significantly called versus the input were retained. Peaks 
were assigned to Refseq annotated genes according to GIN (Cesaroni et al., 2008). 
Intergenic regions were considered as having more than 22kb of distance from the 
nearest gene. Genome tracks were generated using MACS and normalized to the same 
sequencing depth.   
Overlapping peaks were calculated with Galaxy software and were considered as 
regions sharing at least 1 bp between the two datasets. 
Heatmaps for IMRs PR/LSD1 specific were obtained comparing -10*LOG10(pvalue) 
for each region significantly enriched vs the DMSO.  
 
TFBS enrichment analysis 
We used PSCAN for the analysis of gene promoters bound by LSD1. This tool has 
been developed to scan promoters of a given set of genes to find over-represented and 
under-represented TFBS. CLOVER instead calculates p-value of enriched TFBS 
within input sequences generating empirical controls. In detail, Clover scans for 
similarities between the input sequence and a list of Matrix from the Jaspar database 
and experimentally determines the relevant score.  
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Gene expression Analysis 
RNA-seq analysis was performed by using the Cufflinks algorithm (Trapnell et al. 
2010),  Cufflinks is able to re-assemble transcripts to give a quantitative estimation of 
their presence and to calculate differential gene regulation among several samples. 
We decide to adopt a 36 bp paired end sequencing strategy, in order to have a high 
resolution and to also detect relatively low expressed genes. The number of reads 
obtained were comparable among the 5 samples.   
 
Cufflinks does not restrict by prior gene annotation and is able to also detect new 
splice variants or alternative TSS. In detail, the first step of the alignment process 
consists in creating a set of candidate alternative (splice or TSS) transcripts (mutually 
incompatible transcripts) by a series of sequential overlaps among all the reads 
coming from the sequencing.  Once basal transcripts were defined, reads were 
realigned to quantify the relative abundance of each splice or TSS variants.  The value 
that we considered to quantify the relative expression of a given gene corresponds to 
the number of reads aligned per kilobases of the transcript per million mappable 
fragments detected, namely FPKM (fragments per kilobase of exon per million 
fragments mapped). This value has also been used for comparative analysis: “same 
gene different samples”, “same sample different genes”. The heatmap includes all the 
genes that were found to be modulated at least in one sample. The threshold set to 
consider a gene as being regulated was set at FDR ≤0.05 Fold Change ≥2 fold if not 
otherwise indicated.  
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AIMS 
We have characterized a novel LSD1 inhibitor showing high specificity and acting at 
relatively low concentrations (we will refer to this as ”MC”) (Binda, Valente et al. 
2010). By taking advantage of this inhibitor we have been able to investigate the 
mechanistic role of LSD1 in APL. As a model system we used NB4 cells, which are 
derived from an APL patient and recapitulate numerous characteristics of APL 
blasts (Lanotte, Martin-Thouvenin et al. 1991) (Saeed et al., 2012). NB4 cells 
express PML-RAR (PR) and they are insensitive to physiological RA 
concentrations (0.01µM, defined as “RA LOW”). Instead, treatment with 
pharmacological concentrations of RA (1µM, defined as “RA HIGH”) causes cell 
growth arrest and terminal differentiation. The rational behind the RA based therapy 
is that pharmacological doses of RA can overcome the cellular differentiation block, 
induce PR degradation and reactivate PR repressed genes (Chen, Odenike et al. 2010). 
My thesis started from the initial observation that LSD1 inhibition induces sensitivity 
of NB4 cells to physiological concentration of RA and impairs cell growth driving 
cells through differentiation (Binda, Valente et al. 2010). LSD1 is mainly involved in 
transcriptional regulation, in part by modifying the chromatin surrounding regulatory 
regions (Cloos, Christensen et al. 2008) (Whyte, Bilodeau et al. 2012). Therefore, to 
investigate the molecular mechanisms and the underlying dynamics of APL cell 
sensitization we performed a genome wide profiling of both transcriptional and 
epigenetic changes accompanying LSD1 inhibition-primed cell differentiation. 
Moreover, since the current model by which PR represses its target genes involves the 
cooperation with several chromatin modifiers, some of which were also shown to 
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interact with LSD1 in other systems, (Minucci and Pelicci 2006) (Mosammaparast 
and Shi 2010) we investigated the possible direct interplay between LSD1 and PR.  
Taken together, our studies aimed to: 
• Further validate the role of LSD1 in differentiation of APL; 
• Identify the transcriptional networks involved; 
• Define the molecular mechanisms underlying the differentiation block 
mediated by the activity of LSD1, and the interplay of LSD1 with the oncoprotein PR. 
Overall, our studies should provide several novel information regarding the role of 
LSD1 in APL, and hopefully these findings could be extended to other forms of 
cancer. 
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RESULTS 
Inhibition of LSD1 mimics its depletion and has a similar 
effect on cell growth of APL cells 	  
We demonstrated that LSD1 inhibition sensitizes NB4 cells to RA treatment and 
induces cell growth arrest and differentiation when combined with a physiological 
concentration of RA (RA LOW) (Binda, Valente et al. 2010). In order to assess 
whether the effects of the inhibitor were specifically due to its action on LSD1, we 
decided to deplete LSD1 protein levels by a retroviral based knock down strategy. 
We tested 4 sequences (Figure 1) in order to knock down LSD1, three of them 
effectively reduce the protein levels with LSD1 KD vector #5 showing the best 
interfering ability. Then, we verified whether LSD1 depletion affects the RA 
induced growth arrest. The untreated LSD1 KD cells do not show significant 
differences in cell growth in comparison with control cells (NI and scramble), 
while all these three LSD1 interfering sequences enhance the sensitivity of NB4 to 
RA treatment. In particular, NB4 cells become sensitive to a physiological 
concentration of retinoic acid (RA LOW) (Figure 1) suggesting that LSD1 
depletion effectively mimics the effect of LSD1 inhibition, thus confirming a direct 
role of LSD1 in RA sensitization.  
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Figure 1: LSD1 KD recapitulates LSD1 inhibition induced effect on growth arrest in NB4 cells. 
Western blot on extracts derived from NB4 cells infected with scramble and four different LSD1-
interfering retroviral vectors. NI: not infected cells. HDAC3 has been used as a loading control. On the 
right, Cell growth of NB4 cells infected with scramble and LSD1-interfering expressing vectors. Cells 
after puromycin selection were treated with RA at different concentrations: RA LOW (0.01 µM), RA 
intermediate (0.1µM), RA HIGH (1µM). Error bars represent SD of two independent experiments. 
 
 
A transient wave of LSD1 inhibition is sufficient to induce APL cell 
sensitivity to physiological RA concentrations  	  
We wanted to dissect the molecular mechanism underlying the LSD1 contribution to 
APL cell maintenance. In order to understand the temporal window in which LSD1 
dependent regulation is determinant for APL cell growth arrest, we measured 
different durations of treatment of NB4 cells with MC. We performed wash out 
experiments, by removing the LSD1 inhibitor after different intervals of time, while 
the RA LOW was kept continuously in the medium. As observed previously, MC 
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alone and RA LOW treatment induces only a mild response. We confirmed that the 
co-treatment with MC and RA LOW induces cell growth arrest, and interestingly we 
found that 24h of MC treatment in the presence of RA LOW mimics the growth arrest 
observed upon 96h of continuous co-treatment (see Figure 2). Thus, inhibiting LSD1 
activity for 24h is sufficient to sensitize NB4 cells to physiological RA concentrations 
(Figure 2), suggesting that most of the LSD1 dependent regulation occurs in the first 
24h interval of time. For this reason, we selected the 24h timepoint as the treatment 
condition for the subsequent studies (see below). 
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Figure 2: Schematic representation of the wash out experiments and NB4 cell growth evaluation 
upon LSD1 inhibition.  
NB4 cells were co-treated with RA LOW (0.01µM) for 96h and MC 2µM for 6h, 12h and 24h, or as a 
positive control with RA HIGH (1µM) alone. MC was used at 2 µM, the concentration in which it has 
been shown to reach the maximum target modulation (Binda, Valente et al. 2010). NB4 cells were 
plated at 100.000/ml and counted at 96h. Error bars represent SD of four independent experiments. 
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Differentiation accompanies LSD1 inhibition primed growth arrest 	  
Since prolonged co-treatment with MC and physiological doses of RA (96hours of 
continuous co-treatment) leads to differentiation, we wanted to assess if the LSD1 
primed (24h of MC treatment plus 96h of RA LOW) growth arrest was associated 
with cell differentiation. Differentiation is accompanied by the expression of surface 
markers and morphological changes. In particular, APL blasts upon differentiating 
stimuli express neutrophil surface markers and acquire granulocyte-like morphology. 
Main features of granulocytic differentiation include: reduced nucleus/cytoplasm 
ratio, round cellular shape substituted by an irregular morphology and the formation 
of cytoplasmic granules. We decided to characterize morphological changes and 
expression of a differentiation marker on the following samples: cells treated with 
dimethyl sulfoxide (DMSO), cells treated with LSD1 inhibitor alone (MC), cells 
treated with RA 0.01µM alone (RA LOW), cells treated for 24h with MC in presence 
of RA LOW for 96h (from now on, MC/RA LOW), and cells treated for 96h with RA 
1µM (RA HIGH). 
We, therefore, first checked the induction of the expression of CD11b (Figure 3). As 
shown in the qPCR histograms, both RA LOW and MC exhibit a significant effect on 
the expression of this marker and the combination of the two agents causes a stronger 
induction of CD11b expression. We next assessed appearance of differentiation 
morphological features by eosine/methylene blue staining (Figure 3). LSD1 inhibition 
alone is not able to induce any strong morphological change, as well as only a modest 
increase of cytoplasmic fraction was observed in RA LOW treated cells. As expected, 
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cells treated with RA 1µM (RA HIGH) showed lower a ratio between nucleus and 
cytoplasm compared with control cells and some pink/white granule appeared. 
Interestingly, MC/RA LOW co-treated cells were even more differentiated. Indeed, 
MC/RA LOW co-treated cells present: irregular shapes, diffuse granules formation 
and a partial acquirement of a horseshoe shaped nucleus. All the above evidence 
demonstrated a clear cooperative effect between the LSD1 inhibition and the 
physiological RA stimulus in inducing differentiation and growth arrest of APL cells, 
even more pronounced than that induced by pharmacological RA doses.  
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Figure 3: Effects on cellular differentiation upon LSD1 inhibition. RNA extracts from NB4 cells 
after 24h were retro-transcribed and analyzed by qPCR: fold changes normalized versus DMSO and 
gapdh (used as housekeeping) are showed. Error bars represent SD of two independent experiments. 
Cytospin of NB4 cells after 96h of each treatment were stained with May-Grunwald and Giemsa. RA 
LOW and MC treated cells showed modest differentiation while MC/RA LOW and RA HIGH (RA 
1µM) treated cells exhibited stronger differentiation-associated morphological changes. 
 
 
 
LSD1 genomic distribution 
 
LSD1 binds both TSS-proximal and TSS-distal regions in NB4 cells  	  
Since LSD1 mainly functions in multiprotein chromatin modifying complexes that 
regulate gene expression, we decided to assess the genomic distribution of LSD1 and 
to correlate the obtained results with the transcriptomic profiling and with the histone 
modifications associated with its enzymatic activity. Firstly, we characterized the 
specificity of the LSD1 antibody by ChIP-western to perform ChIP-Seq experiments. 
The selected antibody was able to immunoprecipitate LSD1 endogenous protein in a 
dosage-dependent manner, as shown in Figure 4. Thus, we performed ChIP-Seq for 
LSD1 in untreated NB4 cells. We performed q-PCR validation for several regions 
(see Figure 5) and set a threshold to consider a peak validated at –log10 p-value > 
169. LSD1 binds 15,188 regions and more than 45% of them are proximal to the TSS 
(+/- 2500bp) of annotated genes and about 35% of LSD1 peaks lay in intergenic and 
intronic regions, possibly representing enhancer regions (Figure 4), consistent with 
other findings in mESC (Whyte, Bilodeau et al. 2012). 
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LSD1 ChIP-seq NB4 cells 
ChIP%western%LSD1%
 
Figure 4: LSD1 ChIP western and LSD1 genomic distribution. A) ChIP western: 20 x 106 NB4 
cells per each samples were crosslinked with 1% formaldeyde and lysed (see methods). Chromatin was 
sonicated, precleared and samples were immunoprecipitated o.n. at 4°c with 5 and 10 µg of an anti-
LSD1 antibody.  The input represent 5% of the total lysate. The tested antibody is able to 
immunoprecipitate the target protein in a dose-dependent manner. LSD1 ChIP-Seq was performed on 
NB4 untreated cells, Raw sequencing data were analyzed as described in Barozzi et al. (see methods) 
LSD1 binds mostly gene promoters and a significant portion of intergenic regions. Regions spanning 
around the TSS (+/- 2.5Kb) were considered as promoters. Intergenic regions correspond to regions 
more than 22kb distant from the nearest gene.   
 
We validated several genomic regions for the binding of LSD1 at different p-values 
by q-PCR assays and 26/30 regions tested were considered validated, corresponding 
to 86%. We also highlighted that the proportion of the LSD1 distribution between 
promoters and putative enhancer does not change between highly enriched peaks and 
the rest of the binding sites. Interestingly, among the LSD1 binding regions we 
noticed Cd11b and other genes important for myeloid differentiation such as Cebpe 
(Figure 5). 
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Figure 5: LSD1 ChIP-Seq validation. Validation by ChIP-qPCR assay of LSD1 positive regions at 
several p-values in three independent experiments. The first column represents an intergenic region 
negative for LSD1 binding; anti-IgG antibody was used as mock control. Enrichment of the negative 
region plus three times the relative SD was set as threshold: 26/30 regions were considered as 
validated. Genomic distribution of LSD1 peaks in NB4 cells. The two screenshots represent the LSD1 
targ t genes, Cebpe and Icam1:  
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LSD1 binds at promoter regions of genes potentially regulated by 
transcription factors (TFs) required for hematopoietic differentiation 
 
Given the potentiation of differentiation observed upon treatment with MC; one 
prediction would be that LSD1 is involved in controlling the expression of genes 
required for hematopoietic differentiation. In order to characterize the LSD1 bound 
genes, we performed TF binding sites enrichment analysis on the LSD1 bound 
regions in NB4 cells. LSD1 has been shown to cooperate with several TFs, such as 
GFI1/1B, TAL1, SALL4, to regulate transcription of some specific genes in the 
hematopoietic system (Saleque, Kim et al. 2007); (Li, Deng et al. 2012); Hu et al., 
PNAS 2009). We scanned promoter regions of LSD1 bound genes using the PSCAN 
algorithm (Zambelli, Pesole et al. 2009) in order to find over-represented transcription 
factor binding motifs. LSD1 bound promoters showed an enrichment of a large 
number of transcription factors, in particular, SPI1, EGR1, E2F1-3 (Figure 6). 
Interestingly, these TFs play a role in granulocytic/monocytic differentiation. 
Moreover, among the significant enriched position weight matrices we also found 
REST, a known LSD1 recruiter (Mosammaparast and Shi 2010) and the canonical 
PML-RAR binding sequences (RAR:RXR DR5), suggesting that LSD1 can also 
interact with the oncogenic fusion protein characteristic of APL (see below). This 
strongly suggests that LSD1 binds genes probably involved in terminal differentiation 
of APL cells, and that it can interplay with a number of hematopoietic related TFs. 
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Figure 6: PSCAN analysis on LSD1 bound promoters reveals enrichment for hematopoietic-
related TF. This bioinformatic tool scans TFs binding matrixes enriched within the promoter of a 
given gene list and each matrix is ranked according to its p-value. In particular, all the TFs cited were 
represented by more than one matrix. Here we report the best scoring matrix for each TF. A0080.1 
SPI1 (p-value 3.74316E-68); EGR1 with BU0010 Egr1_primary (p-value 1.01E-206); BU0009 
E2F3_primary (p-value 1.4124E-185); BU0008 E2F2_primary (p-value 4.82E-182); MA0024.1 E2F1 
(p-value 3.98452E-37). MA0138.1 REST (p-value 7.08501E-46) MA0159.1 RXR::RAR_DR5 (p-
value 5.12432E-07).  
 
LSD1 dependent transcriptional regulation during APL cell 
differentiation upon treatment with physiological 
concentrations of RA 	  
We then investigated the consequences of LSD1 inhibition and RA treatments on the 
transcription program of APL cells. We performed an RNA-Seq analysis on cells 
treated with MC alone, with RA LOW, cells co-treated with MC/RA LOW and cells 
treated with RA HIGH, compared to untreated control cells –DMSO- (see figure 2). 
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Given the results of the wash-out experiments, we selected 24h as the optimal time 
point to obtain transcriptional information.  
 
LSD1 regulates highly expressed genes 	  
LSD1 has been generally associated with gene repression, so we first assessed if 
LSD1 bound genes were relatively less expressed than all the others. Unexpectedly, 
we found that LSD1 bound genes are more expressed when compared with the LSD1 
unbound ones. Moreover, we observed a strong overlap between LSD1 and POLII 
binding in NB4 cells (Figure 7).  
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Figure 7: LSD1 bound genes are more expressed than LSD1 negative ones. The RNA was prepared 
from NB4 cell extracts and mRNA-seq was performed according to Illumina True-seq technology 
selecting poly-adenylated transcripts (see methods). The box plot shows the median of log2(FPKM), 
FPKM correspond to the relative number of tags of a given transcript obtained in paired end mRNA-
seq (see methods for full explanation).  Expression levels of LSD1 bound genes (LSD1 peak within 22 
kb upstream or in all gene body). POLII binding coordinates in NB4 cells come from the ENCODE 
project (GSM935354).  
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We then evaluated the impact of LSD1 inhibition, to assess the specific activity of 
LSD1 in controlling the gene expression of regulated genes. We focused our attention 
on genes that were regulated (UP or DOWN) upon LSD1 inhibition (treatment with 
MC). Considering all the regulated genes, we saw that 58% were induced while 42% 
were down regulated (see table 1). In particular, we noticed that LSD1 binds 30% 
(34/112 genes) of the all up regulated genes and only the 2.5% (2/80 genes) of the 
down regulated ones. Moreover, when we restricted our analysis to the LSD1 bound 
genes we found that almost all LSD1 regulated genes (97.5%) show up-regulation and 
only a modest portion appeared down regulated (34 up regulated, 2 down regulated 
FDR <0.05, >2 fold change) (Figure 8). This analysis was also repeated with other 
filtering conditions and the ratio between LSD1 bound and unbound remained 
comparable. 
UP regulated 
DOWN regulated 
UP regulated genes 
DOWN regulated genes 
0%#
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Figure 8: LSD1 represses transcription of its target genes. On the left, pies representing all the 
genes regulated upon 24h of MC treatment: LSD1 binds 30% of all induced genes and only 2.5% of 
down-regulated genes. On the right are shown bars representing the percentage of the regulated LSD1 
positive and negative genes. Most of the LSD1 bound genes do not show modulation upon LSD1 
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inhibition but if regulated they result as being almost always induced. The genes considered dynamic 
(up or down) presented FDR <0.05, fold change > or < 2.  
 
Then we moved our attention to the modulation of the expression in all the considered 
treatments (see table 1). We first checked the expression profiling of several known 
RA induced genes in NB4 cells, such as Tgm2 and Rarb (Figure 9 and not shown). 
Tgm2 was observed to be almost not expressed in control cells, while LSD1 inhibition 
alone did not induce any significant regulation, upon RA LOW treatment Tgm2 
exhibits a slight activation, further enhanced in the presence of LSD1 inhibition. 
Moreover, Tgm2 expression increases in a RA concentration-dependent manner 
(Figure 9). The same regulation was also observed for the RarB gene (not shown). 
 
Categories vs DMSO Number of genes 
MC 2 fold.up 112 
RA LOW 2 fold.up 542 
MC/ RA LOW 2 fold.up 989 
RA HIGH 2 fold.up 671 
MC.2 fold.down 80 
RA LOW.2 fold.down 358 
MC/RA LOW 2 fold.down 326 
RA HIGH 2fold.down 346 
 
Table 1: Number of regulated genes. Number of genes regulated at 24h in all the treatments versus 
the DMSO, showing FDR <0.05, fold change > or < 2. 
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LSD1 controls the expression of hematopoietic related genes  	  
In order to have a better understanding on the global modulation of gene expression, 
we plotted a heatmap displaying all the genes regulated in at least one condition 
(Figure 9). MC has a modest impact on the global gene regulation, while RA LOW 
alone induces an appreciable increase of the expression levels of several genes. The 
co-treatment with MC/RA LOW showed a stronger effect on the induction of most of 
the regulated genes. It was also evident that LSD1 is associated with almost all the 
regulated genes (yellow flag on the top of the heatmap) (Figure 9). This led us 
consider LSD1 as a fine-tuner of transcription rather than a mere co-repressor.  
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Figure 9: LSD1 binds almost all the genes regulated upon differentiating treatments in APL cells. 
Snapshot of the Tgm2 gene and its expression (RNA-Seq tracks in blu) in all the experimental 
conditions. Tracks were obtained using MACS and scaled to the same sequencing depth using custom 
scripts. The heatmap shows clusterization of genes regulated in at least one of the 4 treatments against 
the DMSO. The expression levels range from blue (less induced), to red (more induced), while the 
yellow flag represents the LSD1 bindings. 
 
We next assessed if LSD1 regulated genes could be relevant for the differentiation 
and the growth arrest observed in APL cells. Since RA LOW seems to have an impact 
on the transcription, and in order to dissect the genes more likely directly regulated by 
LSD1, we selected LSD1 bound genes specifically up regulated in the co-treatment 
versus both RA LOW and DMSO. Thus, we performed a gene ontology analysis by 
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using the Ingenuity software with standard settings (Figure 10). “Hematopoietic 
system development and function” and “cellular growth and proliferation” resulted 
among the top scoring networks enriched in the dataset. These data suggest that bona 
fide LSD1 dependent gene regulation gives a relevant contribution to APL cell 
differentiation and growth integrating results obtained in other AML systems (Harris, 
Huang et al. 2012); (Schenk, Chen et al. 2012). 
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Figure 10: LSD1 regulates genes involved in hematopoietic development and cell growth. Top 
Networks from Ingenuity analysis, performed on LSD1 bound genes (LSD1 peak within 22 kb 
upstream or in all gene body) specifically up regulated (>1.4 fold) in the co-treatment versus both RA 
LOW and DMSO. The analysis was performed with standard parameters. Below,a screenshot 
repres nting LSD1 binding (LSD1 ChIP-Seq in red) and RNA-Seq tracks (in blue).  
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LSD1 dependent epigenetic modulation is associated with MC 
primed APL cell differentiation 
Since LSD1 has been shown to demethylate lysine 4 of histone H3, (Shi, Lan et al. 
2004) we wanted to analyze a possible role in the modulation of this histone mark. 
H3K4me2 is a PTM involved in promoter and enhancer regulation and could be 
crucial to influence gene poising and activation (Barski, Cuddapah et al. 2007) (Ernst, 
Kheradpour et al. 2011). Thus we performed ChIP-Seq for H3K4me2 in NB4 cells 
upon LSD1 inhibition and all the considered conditions (see table 2).  
Sample 
Number of H3K4me2 
enriched regions 
NB4_DMSO 40585 
NB4_MC 50.721 
NB4_RA_LOW  39286 
NB4_MC RA LOW  45440 
NB4_RA_HIGH 45995 
 
Table 2: H3K4me2 regions enriched. The raw signal was normalized versus input (p-value <0.05). 
Comparable number of regions was obtained in all samples 
 
From 40 to 50 thousand regions were enriched for H3K4me2 in each condition and, 
as expected, about 40% of them were assigned to gene promoters (Figure 11). We 
also found H3K4me2 spreading in intronic and intergenic regions, likely 
corresponding to enhancer regions as suggested by Ernst and colleague (Ernst, 
Kheradpour et al. 2011) 
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Figure 11: H3K4me2 genomic distribution in APL cells. H3Kme2 enriched regions were 
determined by normalizing ChIP-Seq signals versus input. The genomic distribution of the peaks 
remains constant in all treatments. A significant portion of regions is enriched around the TSS of 
annotated genes. 
 
LSD1 localizes at H3K4me2-enriched regions  	  
Our results suggest that LSD1 acts in our system mainly as a transcriptional repressor. 
LSD1 mediated transcriptional repression activity depends mainly on specific 
interactions with several cofactors (Shi, Matson et al. 2005).  BHC80 belongs to the 
LSD1 complex and has been shown in vitro to recruit LSD1 on the unmethylated 
form of histone H3K4 (H3K4me0), linking LSD1 to gene repression (Lan, Collins et 
al. 2007). We consequently wondered whether LSD1 was recruited in regions 
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depleted of H3K4me2. As a first step, we assessed if the LSD1 binding was 
associated with H3K4me2 enriched/not enriched regions. We crossed H3K4me2 and 
LSD1 peaks and we found that 84% of LSD1 peaks fall within regions harboring 
detectable H3K4me2. Therefore, our data suggests that LSD1 preferentially binds 
H3K4me2 positive regions. Moreover, LSD1 and H3K4me2 overlapping sites occur 
both in TSS proximal (56%) and TSS distal (44%) elements. Since LSD1 functions as 
a lysine 4 demethylase (Shi et al., 2004) we reasoned that these LSD1/H3K4me2 
double positive regions should show low levels of H3K4me2. So, we measured the 
level of the H3K4me2 enrichment in the LSD1 positive and the LSD1 negative 
regions. The box plot in Figure 12 clearly demonstrates that LSD1 bound regions 
show higher enrichment in H3K4me2 than the negative ones. This result is in 
accordance with the fact that LSD1 binds relatively more expressed genes and 
suggests that LSD1 activity is needed to modulate H3K4me2 levels, rather than to 
completely remove this histone mark at its binding loci. 
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Figure 12: LSD1 bound regions are enriched for H3K4me2. The Venn diagram shows 
LSD1/H3K4me2 overlapping regions: H3K4me2 peaks in DMSO were crossed with the LSD1 peaks: 
84% of LSD1 binding occurs at H3K4me2 positive regions.  The box plot shows LSD1 positive 
regions (defined as regions which contain at least one LSD1 peak) and LSD1 negative regions. The 
medians of log2 ratio of H3K4me2 tags normalized against input are plotted. LSD1 positive regions 
exhibit stronger H3K4me2 enrichment than the negative ones.  
  
 
Locus specific modulation of H3K4me2 during differentiation of NB4 
cells 	  
We wanted to assess the dynamicity and the regulation of H3K4me2 levels upon NB4 
differentiation due to the LSD1 inhibition and/or RA treatments. We identified 
H3K4me2 increasing regions, normalizing ChIP-Seq signals obtained in all the 
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experimental conditions (see Table 2) against DMSO (see figure 2-3). We will refer 
to these regions as IMRs (increased methylated regions). The distribution of IMRs, in 
each sample, was similar to the basal H3K4me2 signal, indicating that the H3K4me2 
increase involves to the same extent both promoters and distal elements (Figure 13). 
We ended up with 10392 IMRs upon LSD1 inhibition, 4006 in RA LOW, 10858 in 
MC/RA LOW and 15796 in RA high. Of note, the absolute number of IMRs 
suggested that RA low alone has a milder effect on H3K4me2 at genome wide levels 
in comparison with all the other treatments. Indeed, about 4006 IMRs are RA LOW 
dependent while about 10000 IMRs appear concomitantly with the LSD1 inhibition. 
To validate the region specific increase of H3K4me2 in the different samples, we 
independently validated by qPCR a number of regions that show variable enrichment 
profiles. For example, in Figure 14 we report two screenshots and the corresponding 
qPCR analysis of two H3K4me2 regions that are regulated in a very different way. 
The first one is clearly LSD1 inhibitor-dependent while the second one seems to be 
only sensitive to RA. The trend we saw in the ChIP-Seq signals were maintained in 
the qPCR enrichments, where slight differences among the treatments were 
reproducible.  
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MC vs DMSO RA LOW vs DMSO 
MC/RA LOW vs DMSO RA HIGH vs DMSO 
 
Figure 13: IMRs genomic distribution. We defined H3K4me2 increased regions (IMRs), 
normalizing ChIP-Seq signals first versus input and then versus DMSO signals (p-value < 0.05).  
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Figure 14: IMRs validation. A number of H3K4me2 regi ns that showed variable modulation among 
each treatment were validated by qPCR in biological replicates. Regions were selected with the aim to 
include different types of regulation. Enrichment is calculated by normalizing signals versus the 
input;.the mock correspond to IgG antibody. 
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Bona fide LSD1 targets exhibit the largest increase of H3K4me2 
   
Since we had characterized the LSD1 binding sites (Figure 4), we could then 
investigate the direct contribution of LSD1 to the observed K4me2 modulation. First, 
we wanted to characterize whether LSD1 is enriched in IMRs. We merged IMRs 
specifically induced upon LSD1 inhibition with the LSD1 binding dataset. As 
previously shown (Figure 14), LSD1 inhibition induces up-regulation of about 10000 
H3K4me2 regions (vs DMSO) and LSD1 binds almost 15000 genomic loci (Figure 
4). We found about 3000 regions corresponding to 30% of all MC dependent IMRs to 
be bound by LSD1. Moreover, 70% of MC dependent IMRs do not overlap with 
LSD1, suggesting a possible indirect effect of the LSD1 inhibition (Figure 15). We 
expanded the analysis supposing that LSD1 bound regions could be the ones showing 
the stronger H3K4me2 increase. To this end, we divided all the MC dependent IMRs 
in 4 quartiles depending on the relative increase of H3K4me2. The fraction of LSD1 
positive regions increases together with the gain of H3K4me2 upon LSD1 inhibition 
(Figure 15). If we consider the top IMRs (corresponding to the 4th quartile), LSD1 co-
occupancy reaches 45%. Thus, the initial binding of LSD1 is preferentially distributed 
on regions that exhibit the largest regulation of this histone mark. 
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Figure 15: LSD1 binds and regulates IMRs showing the largest increase. A representative 
schematic of MC/LSD1 dependent IMRs is shown on the left. The Venn diagram shows the overlap 
between LSD1 peaks and MC specific IMRs. 3171 regions were LSD1-premarked. Below, the bars 
represent the 4 quartiles in which MC specific IMRs were divided. The division in quartile has been 
done on the base of H3K4me2 enrichment levels. LSD1 binds more than 45% of IMRs belonging to 
the 4th quartile. 
 
Finally, since MC/RA LOW treatment induces differentiation and growth arrest 
(Figure 2-3 and Binda et al., 2010) a clear goal was to dissect the specific impact of 
LSD1 in the regulation of H3K4me2 in this condition. In particular, in order to 
distinguish among the RA LOW dependent IMRs and the contribution of LSD1 
inhibition, we normalized K4me2 ChIP-Seq signals coming from co-treated cells 
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versus the K4me2 RA LOW ChIP-Seq data. The resulting MC specific IMRs 
corresponded to 6338 genomic loci (Figure 16). These regions were distributed 
mainly in TSS-distal portions of the genome. In fact only 15% of IMRs localize 
around TSS (+/- 2500bp) while the remaining 85% occur in introns, exons and 
intergenic regions. These IMRs may represent regulatory regions important for 
differentiation. If that is the case, they should be regulated by specific transcription 
factors and enriched for their binding motifs. In order to investigate which TF could 
have a role in the regulation of MC specific IMRs during differentiation, we 
performed a CLOVER analysis on the regions showing highest enrichment (top 1000) 
(Figure 16). The SPI1 matrix came out among the best scoring ones. This is 
particularly interesting because this TF has been shown to bind and regulate 
enhancers in the myeloid lineage (Ghisletti et al., 2010; Heinz et al., 2010; Pham et 
al., Blood 2012).  Other TF binding motifs involved in the myeloid development also 
resulted as being enriched, such as RUNX1, MZF1 and GFI1. Of note, the latter was 
previously demonstrated to be a direct LSD1 recruiter (Saleque et al., 2007). These 
results sustain the idea that upon LSD1-inhibition specific IMRs could correspond to 
relevant regulatory regions and highlighted a possible interplay between LSD1 and 
master regulators. 
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Figure 16: MC specific IMRs associated with differentiation correspond mainly to TSS distal 
regions and are enriched for TFs important for myeloid development. Schematic representation of 
MC specific IMRs in the MC/RA LOW co-treatment. MC/RA LOW ChIP-Seq signal was normalized 
on RA LOW reads. Shown below is the genomic distribution of the MC specific IMRs: IMRs occur 
preferentially at promoter distal regions. On the right TFs binding motif enrichment was performed on 
top the 1000 MC specific IMRs: top 25 enriched matrixes are reported.  
 
 
We merged this IMRs dataset with LSD1 peaks. We observed that the 27% of IMRs 
harbour an LSD1 peak (Figure 17). We again divided IMRs according to the intensity 
of H3K4me2 enrichment and assessed the correlation with the LSD1 binding. 
Interestingly, LSD1 preferentially occupies IMRs presenting the largest increase of 
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H3K4me2. Moreover, all the regions that were analyzed for the TF binding sites 
enrichment (Figure 16) belong to the 4th quartile, and correspond to the ones showing 
the strongest enrichment in H3K4me2 and the highest overlap with LSD1. 
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Figure 17: LSD1 regulates differentiation associated IMRs showing the largest increase in 
H3K4 e2. A representative schema of MC/LSD1 dependent IMRs is shown on the left. The Venn 
diagra  shows the overlap between LSD1 peaks in DMSO, and MC specific IMRs in the MC/RA 
LOW treated cells: Among the 6338 IMRs, 1692 are LSD1 positive. The bars represent IMRs divided 
in 4 quartiles, the first include regions with less H3K4me2 enrichment while the fourth quartile 
represents IMRs showing the largest increase and the largest fraction of LSD1 peaks.  
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Characterization of the LSD1 – PML-RAR interplay 	  
APL is characterized in 95% of the cases by PML-RAR (PR) expression and this 
translocation is the initiating event in APL as shown by murine models of the disease. 
PR determines the differentiation block and the aberrant proliferation of myeloid 
progenitors. Molecularly, RA activates PR-repressed target genes and mediates its 
proteasome-mediated degradation. While, pharmacological doses of RA (RA HIGH) 
trigger PR degradation, physiological concentrations of RA (RA LOW) do not (Nasr, 
Guillemin et al. 2008). We demonstrated that LSD1 inhibition induces a strong 
differentiation and a growth arrest in the presence of RA at a physiological 
concentration (see Figure 2-3). For this reason, we wanted to understand if the LSD1 
primed differentiation/growth arrest of APL cells was associated with PR degradation. 
A possible explanation may be the synergistic activity of the LSD1 inhibitor and RA 
LOW treatment in the degradation of PR.  
 
LSD1 priming of differentiation occurs in the presence of PR 	  
We analyzed PR protein levels by western blot. We found that PR is almost 
completely degraded by RA HIGH and only started to be degraded by RA LOW 
treatment, while PR remains stable upon LSD1 inhibition alone. Interestingly, PR is 
not degraded in the co-treated cell extracts, presenting level comparable to the ones 
seen in RA LOW alone treated cells. Hence, we were in the condition to assay the 
NB4 differentiation/growth arrest in the presence of the oncogene (Figure 18). Since 
most of the PR oncogenic potential occurs via its function as an aberrant transcription 
factor (Saeed, Logie et al. 2011), we wanted to control whether PR still binds its 
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target genes upon MC/RA LOW treatment. For this reason, we tried to perform a PR 
ChIP-Seq in all our experimental conditions, but probably because of the low quality 
of the commercial antibody available we were unable to do so. We used an anti-PML 
antibody to specifically distinguish PR from the RARalpha receptor and performed 
ChIP-qPCR analysis. We saw that RA causes a concentration-dependent decrease in 
the PR recruitment on both of the regions tested, while LSD1 enzymatic activity does 
not impact upon the PR recruitment to these two binding sites. These results 
demonstrated that LSD1-inhibition triggered differentiation and growth arrest occur 
without PR degradation.  
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Figure 18: LSD1 inhibition does not trigger PML-RAR degradation. Western blot showing PR 
levels in NB4 cells after 24 hours of each treatment. Immunoblotting with an anti-RAR antibody was 
performed o.n.. and a band was deteced at about 120 KD. Tubulin was used as a loading control. 
Below, the histogram represents the ChIP qPCR for PML in NB4 cells. Enrichment was calculated by 
normalizing signal versus input. Two negative regions were used to distinguish aspecific signals. NEG 
REG A corresponds to a PR-negative intergenic region while NEG REG B is an intronic PR-negative 
region, occurring close to a PR peak. 
 
PML-RAR shares most of its binding sites with LSD1 	  
PML-RAR has been shown to induce the differentiation block, in part, by repressing 
its target genes through the cooperation with several histone-modifiers, such as 
HDAC1 (Minucci and Pelicci 2006). Interestingly, HDAC is also found to contribute 
to the LSD1-dependent transcriptional regulation (Shi et al Mol Cell 2005), so we 
asked whether, in turn, LSD1 also cooperates with PR. We assessed if the two 
proteins show common binding sites by intersecting PML-RAR binding coordinates 
(previously established in NB4 by ChIP-Seq, performed with an antibody that was not 
accessible to us)  (Martens et al., Cancer Cell 2010) and LSD1 ChIP-Seq data in NB4 
cells. Strikingly, we found that more than 65% of PML-RAR positive regions overlap 
with LSD1 peaks (Figure 19). Despite that, we encountered a percentage of LSD1 
binding sites not overlapping with PR, thus suggesting the existence of 
complementary LSD1 PR-independent functions (in accordance with previous reports 
in PR deficient AML cells). The overlapping peaks do not show any preferential 
genomic distribution, having a comparable percentage of promoter associated and 
distal peaks (not shown). Two screenshots of some PR/LSD1 overlapping sites are 
shown in Figure 19, representing both TSS proximal and distal common binding 
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regions. The common target genes include genes already shown to be important for 
the NB4 cell differentiation such as Spi1, Tgm2 (Mueller et al., Blood 2006; Csomos 
et al., Blood 2010) and other well known PR targets, such as Pram1. Interestingly, 
one of the most studied PR targets RarB was not bound by LSD1 (not 
shown).
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Figure 9: LSD1 and PR show a large portion of common binding sites. The 2700 PR binding 
regions wer  retrieved from the literature (Martens et al., 2 10) and were merged with LSD1 peaks in 
NB4 cells. About 1800 regions show occupancy by both PR and LSD1. Among the common target 
genes there are also genes important for the hematopoietic development. Below two screenshots 
representing several PR/LSD1 double positive genes, among which are Cebpe and Icam1.  
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PML-RAR expression does not alter LSD1 recruitment 	  
The existence of a large number of common binding sites prompted us to determine 
whether PR recruits LSD1 onto its target sites. In order to address this point we 
choose as a model system the PR9 clone. PR9 cells were obtained from the 
monoblastic U937 cell line by transfection of the PR cDNA under the control of the 
zinc (Zn)-inducible metallothionein promoter (Grignani et al., Cancer Res 1994). In 
this system we can induce PR expression via zinc treatment (Figure 20). We 
performed PML and LSD1 ChIP-Seq both prior to- and after 8h of Zn-dependent 
induction. We observed that the pattern of LSD1 binding in PR9 cells remains largely 
(97% of cases) unchanged by PML-RAR expression, suggesting that PML-RAR is 
not recruiting LSD1 in the early phases of the disease (Figure 20) and that PML-RAR 
expression does not induce the LSD1 displacement from its originals target sites. 
However, we cannot exclude recruitment/displacement occurring in the later phases 
of APL development.  
LSD1%
+Zn% PML+RAR%
+Zn%
PR9%cells%
stable%
increase%
decrease%
2%%
97%%
1%%
LSD1 bindings in PR9 cells upon  
PML-RAR expression are stable  
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Figure 20: LSD1 occupancy does not change upon PR expression. A schematic representation of 
PR9 cells, a PR-inducible system (see methods). In brief, PR expression is under the control of a Zn 
promoter. Upon 8h of 100 µM Zn treatment a portion of cells was saved to verify the overexpression of 
the PR protein and the rest of the cells were fixed.  LSD1 occupancy variation was gauged by 
normalizing ChIP-Seq signal coming from PR9 cells upon 8h of PR induction on the signal obtained 
from untreated cells. Only a modest portion of LSD1 occupancy is altered: only 2% increased and 1% 
decreased their enrichment.  
 
 
A significant portion of PR binding events occurs at LSD1 pre-
marked regions  	  
It has been recently demonstrated that PR binding occurs at genomic region endowed 
with distinct features, such as chromatin accessibility, p300 binding and low 
acetylation levels (Martens et al., Cancer Cell 2010; Saeed et al., Blood 2012). For 
this reason, we asked whether in PR9 cells PR shows a preferential distribution 
relative to the LSD1 binding. We merged LSD1 peaks obtained in un-induced PR9  
cells with the ones of PR. We saw that in about 70% of the cases PR binding occurs in 
an LSD1 pre-marked region (Figure 21). This evidence further confirmed the 
existence of a possible interplay between the two proteins and suggested that PR 
recruitment benefits from LSD1’s presence at a majority of its target regions. 
Moreover, as well as in NB4 cells, some of the commonly bound genes are involved 
in the hematopietic compartment, such as Runx1 (Figure 21). We observed that the 
LSD1 peaks number (48321) was higher in PR9 cells than the ones obtained in NB4 
cells (15188). For this reason, we decided to repeat the analysis by cutting the LSD1 
peaks dataset to the p-value considered reliable in NB4 cells. Despite this higher 
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stringency, the overlap remains highly significant, and PR targets LSD1 positive 
regions in more than 40% of the cases. 
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Figure 21: PR binds LSD1 pre-marked regions. Venn diagram showing PR and LSD1 common 
binding regions. LSD1 coordinates were obtained from un-induced PR9. A schematic representation of 
the PR bi ding in PR9 cells. PR is recruited to LSD1 binding sites and LSD1 does not increase nor 
decrease its enrichment upon PR expression. A representative screenshot of LSD1 and PR overlapping 
peak  on the RUNX1 gene. 
 
 
LSD1 and PR cooperate to regulate regions enriched in H3K4me2  	  
Disruption of the epigenetic landscape has be n suggested as a crucial mechanism by 
which oncofusion proteins induce and maintain the leukemogenic status. (Chen, 
Od nike et al. 2010). To characterize the possible functional outcome of the interplay 
	   93	  
between LSD1 and PR we investigated their correlation with H3K4me2, the main 
epigenetic mark controlled by LSD1. We analyzed the corresponding H3K4me2 
levels within PR- or LSD1- exclusive regions and for the PR/LSD1 double positive 
regions in NB4 cells. We observed that PR-exclusive regions display comparable 
H3K4me2 enrichment in comparison with the double negative ones. Instead, looking 
at the LSD1 binding sites we noticed that the ones shared with PR (in red) display 
lower levels of H3K4me2 in comparison with the LSD1+/PR- (in yellow) (Figure 22). 
This result reveals that LSD1/PR double positive peaks are found in less enriched 
H3K4me2 regions in comparison with the LSD1 exclusive ones. 
  
Log2(#'reads'H3K4me2/#reads'input)'  
Figure 22: LSD1 and PR share regions owing to a specific H3K4me2 enrichment. The box plot 
shows LSD1/PR double negative regions (grey box), LSD1 negative PR positive regions (blue box), 
LSD1 positive/PR negative regions (yellow box), and LSD1/PR double positive regions (red box). The 
medians of log2 ratio of H3K4me2 reads normalized against input are plotted. On the right is shown 
the portion of regions assigned to each category.   
 
We wanted to assess if one aspect of the PR/LSD1 interplay can involve the 
modulation of H3K4me2 levels at commonly regulated sites. To do so, we analyzed 
the H3K4me2 dynamic first in general and then specifically in double positive 
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regions, upon MC/RA LOW treatment (differentiation in presence of PR) and upon 
RA HIGH treatment (differentiation in absence of PR). We initially performed a 
global analysis considering all the IMRs occurring in these two conditions. We found 
that 70% of all IMRs in MC/RA LOW were also induced upon RA HIGH treatment, 
suggesting an overall similarity in their regulation (not shown). Then, we focused our 
attention on PR/LSD1 common target regions. We found that RA HIGH treatment 
causes H3K4me2 increase in 857 (50%) out of 1766 LSD1/PR common peaks, while 
upon MC/RA LOW the increasing regions were observed to be 516. Interestingly 444 
LSD1/PR bound regions, corresponding to 86% of MC/RA LOW induced loci (and 
50% of the RA HIGH induced), were regulated in both conditions. We then wanted to 
gain more insight into the contribution of each treatment (RA LOW and MC) to the 
H3K4me2 modulation. We analyzed PR/LSD1 commonly regulated regions and 
organized them into 4 quartiles according to the extent of H3K4me2 induction upon 
RA HIGH treatment. We plotted the enrichment of all the treatments versus the 
DMSO of all the regulated regions (Figure 23). We saw that in the majority of the 
cases RA LOW and MC given alone have a poor effect on the H3K4me2 regulation.  
Instead, co-treatment triggers an induction of H3K4me2 comparable to the one 
observed in the absence of PR (RA HIGH). This is true also for regions showing 
lower induction (2nd and 1st quartile). This indicates that the LSD1 inhibition in these 
regions can mimic PR depletion and that LSD1 is actually contributing to keep 
H3K4me2 levels under a certain threshold also in a subset of PR positive regions.  
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Figure 23: LSD1/PR commonly regulated IMRs show comparable H3K4me2 dynamics. The 
regions were divided in 4 quartiles according to the extent of H3K4me2 (corresponding to –log2 p-
value of each region) induction upon RA HIGH treatment. The 4th and the 3rd quartiles correspond to 
regions with a higher enrichment.  
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DISCUSSION 
Differentiation accompanies LSD1 depletion and inhibition-primed 
growth arrest and differentiation 	  
Our lab, in collaboration with Antonello Mai and Andrea Mattevi, previously 
developed a new compound working as an LSD1 specific inhibitor, MC (Binda et al., 
2010). Taking advantage of its high specificity we aimed to characterize the role of 
LSD1 in APL.  We found, by morphological characterization and expression analysis 
of a differentiation-associated marker, that LSD1 KD and pharmacological inhibition 
sensitize a PML-RAR expressing APL cell line to RA-induced differentiation. We 
showed that LSD1 inhibition in the presence of physiological concentrations of RA 
has an even stronger effect than the RA alone given at a concentration 100-fold 
higher. These results confirm the importance of LSD1 in the maintenance of APL and 
were in accordance with LSD1’s role in hematopoietic differentiation as originally  
proposed by the Orkin lab (Saleque et al., Mol Cell 2007). Moreover, LSD1 inhibition 
and protein reduction were demonstrated to induce differentiation of RA insensitive 
cells in AML systems (Shenk et al., Nat Med 2012; Harris et al., Cancer Cell 2012). 
We also demonstrated that a pulse of LSD1 inhibition was sufficient to prime APL 
cells to differentiate suggesting that LSD1 dependent activities play a role in the 
initial phases of RA induced differentiation.  
LSD1 genomic distribution 	  
We provide for the first time genome wide information about the LSD1 genomic 
distribution in an acute myeloid leukemia cell line and specifically in NB4 cells that 
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express the PML-RAR fusion protein. We found that LSD1 occupancy in APL cells is 
mainly promoter-associated as its tag density is higher around the TSS of the 
annotated genes. We also found the presence of a significant part of LSD1 peaks in 
promoter distal regions, in accordance with prior results obtained in mES and an 
immature murine granulocytic cell line (Whyte et al., Nature 2012; Kereniy et al., 
eLIFE 2013). 
We also found that promoters bound by LSD1 were enriched for binding matrixes of 
TFs important for the hematopoietic differentiation process, among which PU.1, 
EGR-1 and KL4 are specifically involved in the function of the myeloid 
compartment, thus supporting the idea of LSD1 as a direct regulator of genes relevant 
for the differentiation. In the literature other TFs have been show to recruit LSD1 in 
the hematopoietic development on specific target genes such as GFI1/1B, TAL1 and 
SALL4, (Saleque et al., Mol Cell 2007; Li et al., Oncogene 2012; Hu et al., PNAS 
2009) and our result further increase the pattern of possible LSD1 recruiter/interactor 
suggesting a lineage specific LSD1 dependent regulation consistent with the model 
proposed by Orkin (Saleque et al., Mol Cell 2007). 
 
LSD1 dependent transcriptional control during differentiation 	  
LSD1 has always been supposed to have a dual role in regulating transcription, both 
as a co-repressor and a co-activator (Metzger et al., Nature 2005; Wissman et al., Nat 
cell Bio 2007). In our system, we found LSD1 overlapping with PolII occupancy and 
binding relatively more expressed genes. This may indicate that LSD1 is cooperating 
to keep transcription of target genes under a certain threshold rather than repressing it 
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completely. In accordance with this idea, we found that upon LSD1 inhibition the 
number of all genes both up regulated and down regulated were almost the same 
percentage-wise (112 upregulated, 80 down regulated upon MC treatment: FDR 
<0.05, >2 fold change).  When we restricted this analysis to the LSD1-bound fraction 
we found that almost all LSD1 regulated genes showed up-regulation and only a 
modest portion appeared as down-regulated (34 up regulated, 2 down regulated FDR 
<0.05, >2 fold change). These results were in accordance with a general repressive 
role of LSD1 in the majority of its regulated regions suggested in mES (Whyte et al., 
2012) We also observed that the majority of LSD1 bound genes were not regulated 
upon inhibition alone and undergo only mild activation upon RA LOW treatment 
while their expression strongly increases during co-treatment with LSD1 inhibition in 
the presence of a physiological RA concentration. It is possible that LSD1 activity is 
regulated by RA LOW dependent interactions with specific co-activators according to 
the model proposed in vitro by Shi and colleagues (Shi, Matson et al. 2005) and that 
in this specific chromatin context LSD1 contributes to the modulation of RA LOW 
induced transcription. Another hypothesis can be that such genes need RA LOW 
dependent activators to be transcribed and LSD1 inhibition instead has a poising  
function. 
 
LSD1 dependent epigenetic modulation associated with MC primed 
APL cell differentiation 	  
Two works on other subtypes of myeloid leukemia have analyzed genome wide 
variation of H3K4me2 upon LSD1 depletion or inhibition in the presence and absence 
of RA. In human AML non PML-RAR expressing cell lines, a specific modulation of 
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K4me2 in LSD1 inhibitor/RA co-treated cells around the TSS of hematopoietic 
related genes was shown (Schenk, Chen et al. 2012). Instead, in a mouse model of 
MLL-AF9 of leukemia, the H3K4me2 modulation was specifically associated with 
the oncogene bound genes (Harris, Huang et al. 2012).  
We characterized H3K4me2 modulation in PML-RAR expressing cells. We found 
that H3K4me2 distributes within promoters and TSS distal regions in accordance with 
previous works (Barski et al., 2007; Heintzman et al., 2007). We have shown that 
almost all LSD1 peaks co-localize with H3K4me2 regions in control cells and that 
these regions have higher enrichment than the LSD1 negative ones. This reveals that 
LSD1 does not completely deplete H3K4me2 at its binding regions but could 
contribute to the balance of the methylation together with a methyltransferase on 
these specific loci. A similar model was proposed for HDACs that share acetylated 
genomic region with the acetyltransferases (Wang, Zang et al. 2009).  
We also found many regions to be regulated that increase the enrichment of K4me2 
(IMRs). Interestingly, the ones showing the greatest increase are more likely to be the 
ones bound by LSD1 both in the absence and in the presence of RA LOW.  
IMRs are distributed in both distal and proximal TSS regions and upon LSD1 
inhibition, but upon co-treatment with RA LOW, an LSD1 inhibition specific 
3K4me2 increase occurs preferentially in TSS distal regions (85% of the cases). 
Clover analysis highlighted several myeloid TF binding motifs enriched in the top 
scoring IMRs among which was PU.1, which has been show to regulate enhancers in 
the hematopoietic lineage and specifically in the monocytic compartment (Ghisletti et 
al., Immunity 2010; Pham et al., Blood 2012), thereby supporting the hypothesis that 
these IMRs can be important regulatory regions. The subset of regions which showed 
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H3K4me2 modulation and are not LSD1 bound probably reflect indirect effects of 
LSD1 inhibition. On the other hand, we also encountered LSD1 regions that do not 
show a measurable H3K4me2 increase in our experimental settings. It is possible that 
LSD1’s enzymatic activity in vivo depends on the surrounding chromatin status and 
that in those particular regions LSD1 is not capable of exploiting all of its enzymatic 
potential. This would be consistent with in vitro evidence regarding the influence of a 
number of histone PTMs on the ability of LSD1 to effectively demethylate the lysine 
4 of the histone H3 (Forneris et al., J Biol Chem 2006). Another possibility could be 
that in those sites, LSD1 is acting on non-histone substrates (Nicholson and Chen., 
Epigenetics 2009). 
Collectively our data for the first time dissect the bona fide LSD1 directly controlled 
regions merging the LSD1 binding regions with the H3K4me2 data in APL cells. 
 
Characterization of the LSD1 – PML-RAR interplay 	  
In 95% of cases, APL patients present the expression of PML-RAR (PR) due to the 
translocation (15;17). PML-RAR exploits its oncogenic potential by influencing both 
the PML pathway and the retinoic acid receptor functions. The standard therapeutic 
approach consists in supplying pharmacological doses of RA in order to reactivate the 
downstream RARa pathway and to induce differentiation of APL blasts. 
Pharmacological doses of RA also induce PR degradation, which has been proposed 
as a crucial goal in order to eradicate APL. We observed that LSD1 inhibition and RA 
LOW treatment induces cell differentiation without inducing PR degradation and 
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displacement. Thus LSD1 inhibition can overcome the complete PR degradation to 
reach differentiation and growth arrest of APL cells.  
The mechanism by which PR induces the block of the normal myelopoiesis at the 
promyelocytic stage includes the repression of its target genes by interacting with 
several histone modifiers. This model is based on evidence obtained from only a few 
PR target genes. By merging documented PR bindings sites (Martens, Brinkman et al. 
2010) with our LSD1 targets we noticed that the majority of PR targets are shared 
with LSD1. We also determined that in the initial phases of the disease, LSD1 binding 
is not recruited by PR and also that its physiological binding remains substantially 
unchanged upon PR expression. Moreover, we also discovered that PR binding 
occurs, in the majority of the cases, in regions where LSD1 is already present 
suggesting that PR may benefit from the LSD1 binding. A question that remains open 
is whether LSD1 facilitates the recruitment of PR. It could be possible that LSD1 
works to create a chromatin environment that favours PR localization at its binding 
sites. An analogous correlation has been demonstrated for ERG and AML1-ETO.  In 
fact, AML1-ETO binds regions pre-marked by ERG and ERG is able to facilitate the 
binding of the oncofusion protein (Martens et al., Blood 2012). Genomic regions 
characterized by the presence of both proteins, revealed a typical chromatin 
conformation showing a marked H3K4me2 enrichment. PML-RAR and AML1-ETO 
show a preferential pattern of chromatin features within their bindings sites 
comprising histone acethylation, p300 binding and chromatin accessibility (Saeed S et 
al., 2012). Our data provide further evidence of a distinctive chromatin environment 
surrounding PR binding and specifically in the presence of LSD1.  We also found that 
at LSD1-PR double positive regulated regions, LSD1 inhibition cooperates with 
physiological concentrations of RA to reach a level of H3K4me2 comparable to the 
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one reached in RA high treated cells. Consequently, LSD1 inhibition can overcome 
the incomplete PR degradation to induce an increase in H3K4me2 levels. The K4me2 
increase at LSD1/PR double positive regions is also accompanied by a synergistic 
effect on the expression of the corresponding gene for a subset of targets at this time 
point, including cdkn1a (p21) and itgb2 (CD18). This may mean that the majority of 
these regions become poised for later activation.  
Collectively, our experiments characterized the role of LSD1 in APL suggesting a 
mechanistic interpretation of its action. LSD1 controls most of the genes regulated in 
this system upon differentiating conditions. Its action seems to be mediated by its 
H3K4me2 demethylase activity. LSD1 directly demethylates putative regulatory 
regions and represses genes important for the differentiation of APL. Together with 
PR, LSD1 modulates H3K4me2 levels in a subset of shared PR target genes possibly 
in order to control poising and/or induction in later phases of RA LOW induced 
differentiation in the presence of the fusion protein.  
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